BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis 2011;17:1415-22. [PMID: 21560202 DOI: 10.1002/ibd.21506] [Cited by in Crossref: 403] [Cited by in F6Publishing: 429] [Article Influence: 33.6] [Reference Citation Analysis]
Number Citing Articles
1 Thapaliya G, Eldeghaidy S, Asghar M, Mcging J, Radford S, Francis S, Moran GW. The relationship between Central Nervous System morphometry changes and key symptoms in Crohn’s disease. Brain Imaging and Behavior 2022. [DOI: 10.1007/s11682-022-00742-6] [Reference Citation Analysis]
2 Zisman‐ilani Y, Thompson KD, Siegel LS, Mackenzie T, Crate DJ, Korzenik JR, Melmed GY, Kozuch P, Sands BE, Rubin DT, Regueiro MD, Cross R, Wolf DC, Hanson JS, Schwartz RM, Vrabie R, Kreines MD, Scherer T, Dubinsky MC, Siegel CA. Crohn's disease shared decision making intervention leads to more patients choosing combination therapy: a cluster randomised controlled trial. Aliment Pharmacol Ther 2022. [DOI: 10.1111/apt.17286] [Reference Citation Analysis]
3 Ahmed Ali U, Kiran RP. Surgery for Crohn’s disease: upfront or last resort? Gastroenterology Report 2022;10. [DOI: 10.1093/gastro/goac063] [Reference Citation Analysis]
4 Magrì S, Demurtas M, Onidi MF, Picchio M, Elisei W, Marzo M, Miculan F, Manca R, Dore MP, Quarta Colosso BM, Cicu A, Cugia L, Carta M, Binaghi L, Usai P, Lai M, Chicco F, Fantini MC, Armuzzi A, Mocci G. Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study. World J Clin Cases 2022; 10(30): 10921-10930 [DOI: 10.12998/wjcc.v10.i30.10921] [Reference Citation Analysis]
5 Tavares de Sousa H, Carneiro F. Understanding progression of strictures in ileal Crohn's disease-The importance of setting methodological standards. United European Gastroenterol J 2022. [PMID: 36251489 DOI: 10.1002/ueg2.12327] [Reference Citation Analysis]
6 Fujimura H, Hashimoto S, Shimizu K, Onoda H, Tanabe M, Higashi M, Ogawa R, Goto A, Hamabe K, Nishikawa J, Ito K, Takami T. The Evaluation of Transmural Healing by Low-dose Computed Tomography Enterography in Patients with Crohn's Disease. Intern Med 2022;61:2999-3007. [DOI: 10.2169/internalmedicine.9066-21] [Reference Citation Analysis]
7 Cohen NA, Kliper E, Zamstein N, Ziv-Baran T, Waterman M, Hodik G, Tov AB, Kariv R. Trends in Biochemical Parameters, Healthcare Resource and Medication Use in the 5 Years Preceding IBD Diagnosis: A Health Maintenance Organization Cohort Study. Dig Dis Sci 2022. [PMID: 36221010 DOI: 10.1007/s10620-022-07714-2] [Reference Citation Analysis]
8 Irwin J, Lord A, Ferguson E, Simms LA, Hanigan K, Montoya CA, Radford-Smith G. A Method Using Longitudinal Laboratory Data to Predict Future Intestinal Complication in Patients with Crohn's Disease. Dig Dis Sci 2022. [PMID: 36125595 DOI: 10.1007/s10620-022-07639-w] [Reference Citation Analysis]
9 Yuan G, He Y, Cao QH, Tang MM, Xie ZL, Qiu Y, Zeng ZR, Peng S, Chen MH. Visceral adipose volume is correlated with surgical tissue fibrosis in Crohn's disease of the small bowel. Gastroenterol Rep (Oxf) 2022;10:goac044. [PMID: 36042948 DOI: 10.1093/gastro/goac044] [Reference Citation Analysis]
10 Cavalu S, Sharaf H, Saber S, Youssef ME, Abdelhamid AM, Mourad AAE, Ibrahim S, Allam S, Elgharabawy RM, El-Ahwany E, Amin NA, Shata A, Eldegla M, Atef M, Aboraya M, Mohamed M, Anz N, Elmotelb DA, Gabr F, Elzablawy D, Hamada M, Yehia A, Osama D, Mohammed OA. Ambroxol, a mucolytic agent, boosts HO-1, suppresses NF-κB, and decreases the susceptibility of the inflamed rat colon to apoptosis: A new treatment option for treating ulcerative colitis. FASEB J 2022;36:e22496. [PMID: 35947115 DOI: 10.1096/fj.202200749R] [Reference Citation Analysis]
11 Lerchova T, Hradsky O, Kulich M, Veres G, Dias JA, Sładek M, Kolacek S, Van Biervliet S, Melek J, Serban DE, Winther K, de Meij T, Schwarz J, Kolho KL, Escher JC, Bronsky J. Prediction of thiopurine failure in pediatric Crohn's disease: pediatric IBD Porto group of ESPGHAN. Pediatr Res 2022. [PMID: 36008595 DOI: 10.1038/s41390-022-02270-x] [Reference Citation Analysis]
12 Wickramasinghe D, Carvello M, Di Candido F, Maroli A, Adegbola S, Sahnan K, Morar P, Spinelli A, Warusavitarne J. Factors associated with stoma formation in ileocolic resection for Crohn's disease and the development of a predictive scoring system. Langenbecks Arch Surg 2022. [PMID: 35906298 DOI: 10.1007/s00423-022-02626-1] [Reference Citation Analysis]
13 Yu S, Kalinin AA, Paraskevopoulou MD, Maruggi M, Cheng J, Tang J, Icke I, Luo Y, Wei Q, Scheibe D, Hunter J, Singh S, Nguyen D, Carpenter AE, Horman SR. Integrating inflammatory biomarker analysis and artificial intelligence-enabled image-based profiling to identify drug targets for intestinal fibrosis.. [DOI: 10.1101/2022.06.08.495258] [Reference Citation Analysis]
14 Wilkens R, Liao D, Gregersen H, Glerup H, Peters DA, Buchard C, Tøttrup A, Krogh K. Biomechanical Properties of Strictures in Crohn’s Disease: Can Dynamic Contrast-Enhanced Ultrasonography and Magnetic Resonance Enterography Predict Stiffness? Diagnostics 2022;12:1370. [DOI: 10.3390/diagnostics12061370] [Reference Citation Analysis]
15 Gana JC, Sepúlveda A, Orlanski-meyer E, Villarroel del Pino LA, de la Piedra Bustamante MJ, Olivares Labbe MT; Cochrane Gut Group. Tumour necrosis factor-alpha antagonists for treatment of paediatric Crohn’s disease. Cochrane Database of Systematic Reviews 2022;2022. [DOI: 10.1002/14651858.cd014497] [Reference Citation Analysis]
16 Saito S, Ueno N, Kamikokura Y, Sugiyama Y, Kobayashi Y, Murakami Y, Kunogi T, Sasaki T, Takahashi K, Ando K, Kashima S, Moriichi K, Tanabe H, Tanino M, Okumura T, Fujiya M. Gastro-colic Fistula-associated Hypersplenism Causes Pancytopenia in a Patient with Crohn's Disease: A Case Report. Intern Med 2022. [PMID: 35598997 DOI: 10.2169/internalmedicine.9590-22] [Reference Citation Analysis]
17 Aarts P, van der Zee HH. Damage in hidradenitis suppurativa: receiving the deserved attention. Br J Dermatol 2022. [PMID: 35508388 DOI: 10.1111/bjd.21611] [Reference Citation Analysis]
18 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
19 Shen W, Huang X, Liu R, Li C, Li Y, Zhu W. Perforating and nonperforating indications in repeated surgeries for Crohn’s disease. WJCC 2022;10:2733-42. [DOI: 10.12998/wjcc.v10.i9.2733] [Reference Citation Analysis]
20 Shen WS, Huang XH, Liu RQ, Li CY, Li Y, Zhu WM. Perforating and nonperforating indications in repeated surgeries for Crohn’s disease. World J Clin Cases 2022; 10(9): 2731-2740 [DOI: 10.12998/wjcc.v10.i9.2731] [Reference Citation Analysis]
21 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
22 Marín-jiménez I, Acosta MB, Esteve M, Castro-laria L, García-lópez S, Ceballos D, Echarri A, Martín-arranz MD, Busquets D, Llaó J, Navarro-llavat M, Huguet JM, Argüelles-arias F, Vicente R, Boudet JM, Díaz G, Sánchez-migallón AM, Casellas F. Rapidity of clinical response to adalimumab and improvement of quality of life in luminal Crohn's disease: RAPIDA study. Gastroenterología y Hepatología (English Edition) 2022;45:165-176. [DOI: 10.1016/j.gastre.2021.04.007] [Reference Citation Analysis]
23 Sutton RT, Zai Ane OR, Goebel R, Baumgart DC. Artificial intelligence enabled automated diagnosis and grading of ulcerative colitis endoscopy images. Sci Rep 2022;12:2748. [PMID: 35177717 DOI: 10.1038/s41598-022-06726-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
24 Oh K, Oh EH, Noh SM, Park SH, Kim N, Hwang SW, Park SH, Yang D, Byeon J, Myung S, Yang S, Ye BD. Combined Endoscopic and Radiologic Healing Is Associated With a Better Prognosis Than Endoscopic Healing Only in Patients With Crohn's Disease Receiving Anti-TNF Therapy. Clin Transl Gastroenterol 2022;Publish Ahead of Print. [DOI: 10.14309/ctg.0000000000000442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Carvello M, Danese S, Spinelli A. Surgery versus Medical Therapy in Luminal Ileocecal Crohn's Disease. Clin Colon Rectal Surg 2022;35:072-7. [DOI: 10.1055/s-0041-1740031] [Reference Citation Analysis]
26 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
27 Huang Y, Yao D, Guo F, Zhou Z, Li Y. Preoperative Anti-TNF Therapy is Associated with a Shorter Length of Resected Bowel in Patients Undergoing Ileocolic Resection for Crohn's Disease. J Invest Surg 2022;:1-9. [PMID: 34983280 DOI: 10.1080/08941939.2021.2023713] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 le Berre C, Ricciuto A, Peyrin-Biroulet L, Turner D. Evolving Short- and Long-Term Goals of Management of Inflammatory Bowel Diseases: Getting It Right, Making It Last. Gastroenterology 2022:S0016-5085(21)04067-1. [PMID: 34995529 DOI: 10.1053/j.gastro.2021.09.076] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
29 Macaluso FS, Cappello M, Crispino F, Grova M, Privitera AC, Piccillo G, Magnano A, Ferracane C, Belluardo N, Giangreco E, Fries W, Viola A, Di Mitri R, Mocciaro F, Camilleri S, Garufi S, Renna S, Casà A, Maida M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease. Dig Liver Dis 2021:S1590-8658(21)00887-2. [PMID: 34924320 DOI: 10.1016/j.dld.2021.11.021] [Reference Citation Analysis]
30 Belousova EA, Kozlov IG, Abdulganieva DI, Alexeeva OP, Gubonina IV, Lishchinskaya AA, Tarasova LV, Chashkova EY, Shapina MV, Shifrin OS, Shchukina OB. Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021). Alʹm klin med 2021;49:485-495. [DOI: 10.18786/2072-0505-2021-49-060] [Reference Citation Analysis]
31 Laharie D, D'Haens G, Nachury M, Lambrecht G, Bossuyt P, Bouhnik Y, Louis E, Janneke van der Woude C, Buisson A, Van Hootegem P, Allez M, Filippi J, Brixi H, Gilletta C, Picon L, Baert F, Vermeire S, Duveau N, Peyrin-Biroulet L. Steroid-Free Deep Remission at One Year Does Not Prevent Crohn's Disease Progression: Long-Term Data From the TAILORIX Trial. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01268-4. [PMID: 34843987 DOI: 10.1016/j.cgh.2021.11.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Ben-Horin S, Novack L, Mao R, Guo J, Zhao Y, Sergienko R, Zhang J, Kobayashi T, Hibi T, Chowers Y, Peyrin-Biroulet L, Colombel JF, Kaplan GG, Chen MH. Efficacy of biologic drugs in short-duration versus long-duration inflammatory bowel disease: A systematic review and an individual-patient data meta-analysis of randomized controlled trials. Gastroenterology 2021:S0016-5085(21)03709-4. [PMID: 34757139 DOI: 10.1053/j.gastro.2021.10.037] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
33 Mantzaris GJ, Zeglinas C, Theodoropoulou A, Koutroubakis I, Orfanoudaki E, Katsanos K, Christodoulou D, Michalopoulos G, Tzouvala M, Moschovis D, Michopoulos S, Zampeli E, Soufleris K, Ilias A, Chatzievangelinou C, Kyriakakis A, Antachopoulou K, Karmiris K. The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study. Crohn's & Colitis 360 2021;3. [DOI: 10.1093/crocol/otab064] [Reference Citation Analysis]
34 Majidova K, Handfield J, Kafi K, Martin RD, Kubinski R. Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review. Genes (Basel) 2021;12:1465. [PMID: 34680860 DOI: 10.3390/genes12101465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Takabayashi K, Hosoe N, Kato M, Hayashi Y, Miyanaga R, Nanki K, Fukuhara K, Mikami Y, Mizuno S, Sujino T, Mutaguchi M, Naganuma M, Yahagi N, Ogata H, Kanai T. Efficacy of Novel Ultrathin Single-Balloon Enteroscopy for Crohn's Disease: A Propensity Score-Matched Study. Gut Liver 2020;14:619-25. [PMID: 31818049 DOI: 10.5009/gnl19228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
36 Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A. Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy. J Crohns Colitis 2020;14:1524-34. [PMID: 32533769 DOI: 10.1093/ecco-jcc/jjaa098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
37 Ahmad R, Ajlan AM, Eskander AA, Alhazmi TA, Khashoggi K, Wazzan MA, Abduljabbar AH. Magnetic resonance imaging in the management of Crohn's disease: a systematic review and meta-analysis. Insights Imaging 2021;12:118. [PMID: 34406519 DOI: 10.1186/s13244-021-01064-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
38 Bufman H, Eliakim R, Tau N, Amitai MM. Magnetic resonance enterography in Crohn's disease patients: current state of the art and future perspectives. Expert Rev Med Devices 2021;18:657-67. [PMID: 34109891 DOI: 10.1080/17434440.2021.1939682] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Zhan S, Li N, Liu C, Mao R, Wu D, Li T, Chen M, Zhuang X, Zeng Z. Intestinal Fibrosis and Gut Microbiota: Clues From Other Organs. Front Microbiol 2021;12:694967. [PMID: 34335525 DOI: 10.3389/fmicb.2021.694967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
40 Zilbauer M, Heuschkel R. Disease Prognostic Biomarkers in Inflammatory Bowel Diseases—A Reality Check. Journal of Crohn's and Colitis 2021. [DOI: 10.1093/ecco-jcc/jjab118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
41 Shi L, Lu BL, Qiu Y, Huang L, Huang SY, Mao R, Lin JJ, Du JF, Feng ST, Li ZP, Sun CH, Li XH. Hepatic mosaic enhancement pattern correlates with increased inflammatory activity and adverse therapeutic outcomes in patients with Crohn's disease. Abdom Radiol (NY) 2021;46:3149-58. [PMID: 33646351 DOI: 10.1007/s00261-021-02979-z] [Reference Citation Analysis]
42 Schaefer M, Laurent V, Grandmougin A, Vuitton L, Bourreille A, Luc A, Clerc-Urmes I, Orry X, Frampas E, De Billy M, Pouillon L, Le Berre C, Gay C, Meyer J, Baumann C, Peyrin-Biroulet L. A Magnetic Resonance Imaging Index to Predict Crohn's Disease Postoperative Recurrence: The MONITOR Index. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00699-6. [PMID: 34216820 DOI: 10.1016/j.cgh.2021.06.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Takeda T, Kishi M, Takatsu N, Takada Y, Beppu T, Miyaoka M, Hisabe T, Ueki T, Arima H, Hirai F, Yao K. Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies. Dig Endosc 2021. [PMID: 34185921 DOI: 10.1111/den.14073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lukáš M. Treating inflammatory bowel diseases in the 21<sup>st</sup> century: individualized therapy and telemedicine. Vnitr Lek 2021;67:201-205. [DOI: 10.36290/vnl.2021.053] [Reference Citation Analysis]
45 Sparrow MP. Quantification of Digestive Disease Damage in Crohn's Disease, Are We There Yet With the Lémann Index? Gastroenterology 2021;161:800-2. [PMID: 34175282 DOI: 10.1053/j.gastro.2021.06.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Jauregui-Amezaga A, Rimola J. Role of Intestinal Ultrasound in the Management of Patients with Inflammatory Bowel Disease. Life (Basel) 2021;11:603. [PMID: 34201630 DOI: 10.3390/life11070603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Buisson A, Filippi J, Amiot A, Cadiot G, Allez M, Marteau P, Bouhnik Y, Pineton de Chambrun G, Pelletier AL, Nancey S, Moussata D, Attar A, Blain A, Vuitton L, Vernier-Massouille G, Seksik P, Nachury M, Dupas JL, Laharie D, Peyrin-Biroulet L, Louis E, Mary JY. Defining and Assessing the Reproducibility of Crohn's Disease Endoscopic Lesions: A Delphi-like Method from the GETAID. J Crohns Colitis 2021;15:1000-8. [PMID: 33313808 DOI: 10.1093/ecco-jcc/jjaa250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Grandmougin A, D'Amico F, Remen T, Danese S, Bonneton M, Galloy MA, Peyrin-Biroulet L, Laurent V. Role of Cross-Sectional Imaging in Pediatric Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34159487 DOI: 10.1007/s10620-021-07016-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Pariente B, Torres J, Burisch J, Arebi N, Barberio B, Duricova D, Ellul P, Goldis A, Kaimakliotis I, Katsanos K, Krznaric Ž, McNamara D, Pedersen N, Sebastian S, Azahaf M, Weimers P, Lung P, Lacognata C, Horak M, Christodoulou D, Domislovic V, Murphy I, Lambert J, Ungaro R, Colombel JF, Mary JY. Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. Gastroenterology 2021;161:853-864.e13. [PMID: 34052277 DOI: 10.1053/j.gastro.2021.05.049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
50 Maida M, Morreale GC, Sferrazza S, Sinagra E, Scalisi G, Vitello A, Vettori G, Rossi F, Catarella D, Di Bartolo CE, Schillaci D, Raimondo D, Camilleri S, Orlando A, Macaluso FS. Effectiveness and safety of 1L PEG-ASC preparation for colonoscopy in patients with inflammatory bowel diseases. Dig Liver Dis 2021;53:1171-7. [PMID: 33994129 DOI: 10.1016/j.dld.2021.04.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
51 Janssen L, Romberg-Camps M, van Bodegraven A, Haans J, Aquarius M, Boekema P, Munnecom T, Brandts L, Joore M, Masclee A, Jonkers D, Pierik M. Control Crohn Safe with episodic adalimumab monotherapy as first-line treatment study (CoCroS): study protocol for a randomised controlled trial. BMJ Open 2021;11:e042885. [PMID: 33947729 DOI: 10.1136/bmjopen-2020-042885] [Reference Citation Analysis]
52 Avery P. The cost of treating inflammatory bowel disease: step-up vs step-down, therapeutic drug monitoring and personalised medicine. Gastrointestinal Nursing 2021;19:18-24. [DOI: 10.12968/gasn.2021.19.4.18] [Reference Citation Analysis]
53 Agrawal M, Spencer EA, Colombel JF, Ungaro RC. Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists. Gastroenterology 2021;161:47-65. [PMID: 33940007 DOI: 10.1053/j.gastro.2021.04.063] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 19.0] [Reference Citation Analysis]
54 Kennedy NA. Integrating a treat to target approach into clinical practice in 2020. J Gastroenterol Hepatol 2021;36 Suppl 1:6-7. [PMID: 33817849 DOI: 10.1111/jgh.15446] [Reference Citation Analysis]
55 Rivière P, Vermeire S, Irles-depe M, Van Assche G, Rutgeerts P, Denost Q, Wolthuis A, D’hoore A, Laharie D, Ferrante M. Rates of Postoperative Recurrence of Crohn’s Disease and Effects of Immunosuppressive and Biologic Therapies. Clinical Gastroenterology and Hepatology 2021;19:713-720.e1. [DOI: 10.1016/j.cgh.2020.03.064] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
56 Calabrese E, Rispo A, Zorzi F, De Cristofaro E, Testa A, Costantino G, Viola A, Bezzio C, Ricci C, Prencipe S, Racchini C, Stefanelli G, Allocca M, Scotto di Santolo S, D'Auria MV, Balestrieri P, Ricchiuti A, Cappello M, Cavallaro F, Guarino AD, Maconi G, Spagnoli A, Monteleone G, Castiglione F. Ultrasonography Tight Control and Monitoring in Crohn's Disease During Different Biological Therapies: A Multicenter Study. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00340-2. [PMID: 33775896 DOI: 10.1016/j.cgh.2021.03.030] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 13.0] [Reference Citation Analysis]
57 Wang Y, Makadia R, Knoll C, Hardin J, Voss EA, Fife D, Davis K, Sloan S. Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration. BMC Gastroenterol 2021;21:121. [PMID: 33731009 DOI: 10.1186/s12876-021-01708-6] [Reference Citation Analysis]
58 Verstockt B, Noor NM, Marigorta UM, Pavlidis P, Deepak P, Ungaro RC; Scientific Workshop Steering Committee . Results of the Seventh Scientific Workshop of ECCO: Precision Medicine in IBD-Disease Outcome and Response to Therapy. J Crohns Colitis 2021;15:1431-42. [PMID: 33730756 DOI: 10.1093/ecco-jcc/jjab050] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
59 Navarrete J, González-moret R, Cortés X, Lisón JF, Soria JM, Baños RM, Cebolla A. Dispositional Mindfulness and Inflammatory Bowel Disease: Mindful Awareness Mediates the Relation Between Severity and Quality of Life, Stress, and Fatigue. Mindfulness 2021;12:1524-33. [DOI: 10.1007/s12671-021-01620-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
60 Shiga H, Abe I, Kusaka J, Shimoyama Y, Moroi R, Kuroha M, Kakuta Y, Kinouchi Y, Masamune A. Capsule Endoscopy Is Useful for Postoperative Tight Control Management in Patients with Crohn's Disease.Dig Dis Sci. 2021;. [PMID: 33495918 DOI: 10.1007/s10620-021-06841-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Xiong Y, Mizuno T, Colman R, Hyams J, Noe JD, Boyle B, Tsai YT, Dong M, Jackson K, Punt N, Rosen MJ, Denson LA, Vinks AA, Minar P. Real-World Infliximab Pharmacokinetic Study Informs an Electronic Health Record-Embedded Dashboard to Guide Precision Dosing in Children with Crohn's Disease. Clin Pharmacol Ther 2021;109:1639-47. [PMID: 33354765 DOI: 10.1002/cpt.2148] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
62 Le Berre C, Peyrin-Biroulet L; SPIRIT-IOIBD study group. Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease: the SPIRIT Consensus From the IOIBD. Gastroenterology 2021;160:1452-1460.e21. [PMID: 33421515 DOI: 10.1053/j.gastro.2020.10.065] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
63 Rodrigues BL, Mazzaro MC, Nagasako CK, Ayrizono MLS, Fagundes JJ, Leal RF. Assessment of disease activity in inflammatory bowel diseases: Non-invasive biomarkers and endoscopic scores. World J Gastrointest Endosc 2020; 12(12): 504-520 [PMID: 33362904 DOI: 10.4253/wjge.v12.i12.504] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
64 Lee SH, Walshe M, Oh EH, Hwang SW, Park SH, Yang DH, Byeon JS, Myung SJ, Yang SK, Greener T, Weizman AV, Silverberg MS, Ye BD. Early Changes in Serum Albumin Predict Clinical and Endoscopic Outcomes in Patients With Ulcerative Colitis Starting Anti-TNF Treatment. Inflamm Bowel Dis. 2020;. [PMID: 33269403 DOI: 10.1093/ibd/izaa309] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
65 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
66 Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, Allocca M, Maconi G, de Voogd F, Christensen B, Vaughan R, Palmela C, Carter D, Wilkens R. Expert Consensus on Optimal Acquisition and Development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: A Reliability and Inter-rater Variability Study on Intestinal Ultrasonography in Crohn's Disease. J Crohns Colitis 2021;15:609-16. [PMID: 33098642 DOI: 10.1093/ecco-jcc/jjaa216] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 16.0] [Reference Citation Analysis]
67 Hattori S, Nakamura M, Yamamura T, Maeda K, Sawada T, Mizutani Y, Yamamoto K, Ishikawa T, Furukawa K, Ohno E, Honda T, Kawashima H, Ishigami M, Hirooka Y, Fujishiro M. The microbiome can predict mucosal healing in small intestine in patients with Crohn's disease. J Gastroenterol 2020;55:1138-49. [PMID: 33067682 DOI: 10.1007/s00535-020-01728-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
68 Halawani H, Abduljabbar A, Wazzan M, Hashem DA, Baumann C, Luc A, Peyrin-Biroulet L, Saadah OI, Mosli M. Bowel Damage at Diagnosis Using the Lémann Index Score in Saudi Arabian Patients With Crohn's Disease. Cureus 2020;12:e10912. [PMID: 33194479 DOI: 10.7759/cureus.10912] [Reference Citation Analysis]
69 Lambin T, Amiot A, Stefanescu C, Gornet JM, Seksik P, Laharie D, Reenaers C, Bourreille A, Cadiot G, Carbonnel F, Dib N, Fumery M, Gilletta de St Joseph C, Filippi J, Viennot S, Plastaras L, Coffin B, Serrero M, Nahon S, Pineton de Chambrun G, Rahier JF, Roblin X, Boualit M, Bouguen G, Peyrin-Biroulet L, Pariente B; UGT-CD-stricture GETAID study group. Long-term outcome of Crohn's disease patients with upper gastrointestinal stricture: A GETAID study. Dig Liver Dis 2020;52:1323-30. [PMID: 32962965 DOI: 10.1016/j.dld.2020.08.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
70 Greer MC, Cytter-Kuint R, Pratt LT, Soboleski D, Focht G, Castro DA. Clinical-stage Approaches for Imaging Chronic Inflammation and Fibrosis in Crohn's Disease. Inflamm Bowel Dis 2020;26:1509-23. [PMID: 32946578 DOI: 10.1093/ibd/izaa218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Laterza L, Ainora ME, Garcovich M, Galasso L, Poscia A, Di Stasio E, Lupascu A, Riccardi L, Scaldaferri F, Armuzzi A, Rapaccini GL, Gasbarrini A, Pompili M, Zocco MA. Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNFα therapy. Dig Liver Dis 2021;53:729-37. [PMID: 32900648 DOI: 10.1016/j.dld.2020.08.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 Miyoshi J, Saito D, Nakamura M, Miura M, Mitsui T, Kudo T, Murakami S, Matsuura M, Hisamatsu T. Half-Elemental Diet Shifts the Human Intestinal Bacterial Compositions and Metabolites: A Pilot Study with Healthy Individuals. Gastroenterol Res Pract 2020;2020:7086939. [PMID: 32831827 DOI: 10.1155/2020/7086939] [Reference Citation Analysis]
73 Yanai H, Goren I, Godny L, Maharshak N, Ron Y, Avni Biron I, Leibovitzh H, Banai Eran H, Aharoni Golan M, Rabinowitz K, Ziv Baran T, Lavie I, Yadgar K, Zonensain K, Kopylov U, Ben Horin S, Eliakim R, Waterman M, Chowers Y, Ben-Shachar S, Dotan I; Israeli IBD Research Nucleus. Early Indolent Course of Crohn's Disease in Newly Diagnosed Patients Is Not Rare and Possibly Predictable. Clin Gastroenterol Hepatol 2021;19:1564-1572.e5. [PMID: 32629126 DOI: 10.1016/j.cgh.2020.06.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
74 Zittan E, Gralnek IM, Berns MS. The New Proactive Approach and Precision Medicine in Crohn's Disease. Biomedicines 2020;8:E193. [PMID: 32635316 DOI: 10.3390/biomedicines8070193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
75 Choe YH. Precision medicine for pediatric inflammatory bowel disease: a perspective. Precis Future Med 2020;4:43-52. [DOI: 10.23838/pfm.2020.00058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
76 Pershko AM, Grinevich VB, Solovyov IA, Kurilo DP. Modern strategies of therapeutic and surgical treatment of Crohn’s disease. jour 2020;174:89-95. [DOI: 10.31146/1682-8658-ecg-176-4-89-95] [Reference Citation Analysis]
77 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
78 González-lama Y, Sanz J, Bastida G, Campos J, Ferreiro R, Joven B, Gutiérrez A, Juanola X, Sicilia B, Veroz R, Gisbert JP, Chaparro M, Domènech E, Esteve M, Gomollón F. Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. Gastroenterología y Hepatología (English Edition) 2020;43:273-283. [DOI: 10.1016/j.gastre.2020.01.003] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
79 Choi SY, Choi YO, Choe YH, Kang B. Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients. J Korean Med Sci 2020;35:e114. [PMID: 32329259 DOI: 10.3346/jkms.2020.35.e114] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
80 Yoo JH, Holubar S, Rieder F. Fibrostenotic strictures in Crohn's disease. Intest Res 2020;18:379-401. [PMID: 32259917 DOI: 10.5217/ir.2019.09148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
81 González-Lama Y, Sanz J, Bastida G, Campos J, Ferreiro R, Joven B, Gutiérrez A, Juanola X, Sicilia B, Veroz R, P Gisbert J, Chaparro M, Domènech E, Esteve M, Gomollón F. Recommendations by the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the treatment of patients with inflammatory bowel disease associated with spondyloarthritis. Gastroenterol Hepatol 2020;43:273-83. [PMID: 32247533 DOI: 10.1016/j.gastrohep.2020.01.005] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
82 Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, Kaser A, Peyrin-Biroulet L, Danese S. Crohn's disease.Nat Rev Dis Primers. 2020;6:22. [PMID: 32242028 DOI: 10.1038/s41572-020-0156-2] [Cited by in Crossref: 162] [Cited by in F6Publishing: 172] [Article Influence: 81.0] [Reference Citation Analysis]
83 Lauriot Dit Prevost C, Azahaf M, Nachury M, Branche J, Gerard R, Wils P, Lambin T, Desreumaux P, Ernst O, Pariente B. Bowel damage and disability in Crohn's disease: a prospective study in a tertiary referral centre of the Lémann Index and Inflammatory Bowel Disease Disability Index. Aliment Pharmacol Ther 2020;51:889-98. [PMID: 32221985 DOI: 10.1111/apt.15681] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
84 Pellino G, Keller DS, Sampietro GM, Angriman I, Carvello M, Celentano V, Colombo F, Di Candido F, Laureti S, Luglio G, Poggioli G, Rottoli M, Scaringi S, Sciaudone G, Sica G, Sofo L, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): Crohn's disease. Tech Coloproctol 2020;24:421-48. [PMID: 32172396 DOI: 10.1007/s10151-020-02183-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
85 Courbette O, Aupiais C, Viala J, Hugot J, Roblin X, Candon S, Louveau B, Chatenoud L, Martinez-vinson C. Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease. Journal of Pediatric Gastroenterology & Nutrition 2020;70:310-7. [DOI: 10.1097/mpg.0000000000002536] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
86 Krzesiek E, Nienartowicz E, Iwańczak B. Value of magnetic resonance enterography in diagnosis and treatment follow up in Crohn's disease in children. Adv Med Sci 2020;65:214-22. [PMID: 32087571 DOI: 10.1016/j.advms.2020.01.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Guglielmo FF, Anupindi SA, Fletcher JG, Al-hawary MM, Dillman JR, Grand DJ, Bruining DH, Chatterji M, Darge K, Fidler JL, Gandhi NS, Gee MS, Grajo JR, Huang C, Jaffe TA, Park SH, Rimola J, Soto JA, Taouli B, Taylor SA, Baker ME. Small Bowel Crohn Disease at CT and MR Enterography: Imaging Atlas and Glossary of Terms. RadioGraphics 2020;40:354-75. [DOI: 10.1148/rg.2020190091] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 17.5] [Reference Citation Analysis]
88 Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874-883. [PMID: 30908297 DOI: 10.14309/ajg.0000000000000183] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 53.5] [Reference Citation Analysis]
89 Fiorino G, Bonifacio C, Allocca M, Danese S. Impact of therapies on bowel damage in Crohn's disease. United European Gastroenterol J 2020;8:410-7. [PMID: 32213030 DOI: 10.1177/2050640620908696] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
90 Frasca JD, Cheifetz AS. The cost and benefit of anti-TNF therapy from a population perspective-for what it's worth. Ann Transl Med 2019;7:S388. [PMID: 32016106 DOI: 10.21037/atm.2019.12.86] [Reference Citation Analysis]
91 Murthy SK, Begum J, Benchimol EI, Bernstein CN, Kaplan GG, McCurdy JD, Singh H, Targownik L, Taljaard M. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut 2020;69:274-82. [PMID: 31196874 DOI: 10.1136/gutjnl-2019-318440] [Cited by in Crossref: 89] [Cited by in F6Publishing: 95] [Article Influence: 44.5] [Reference Citation Analysis]
92 Jackson BD, De Cruz P. Quality of Care in Patients With Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:479-89. [PMID: 30169698 DOI: 10.1093/ibd/izy276] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
93 Minordi LM, Larosa L, Belmonte G, Scaldaferri F, Poscia A, Gasbarrini A, Manfredi R. Crohn's disease activity before and after medical therapy evaluated by MaRIA score and others parameters in MR Enterography. Clin Imaging 2020;62:1-9. [PMID: 32014620 DOI: 10.1016/j.clinimag.2020.01.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
94 Ryan ÉJ, Orsi G, Boland MR, Syed AZ, Creavin B, Kelly ME, Sheahan K, Neary PC, Kavanagh DO, Mcnamara D, Winter DC, O’riordan JM. Meta-analysis of early bowel resection versus initial medical therapy in patient's with ileocolonic Crohn's disease. Int J Colorectal Dis 2020;35:501-12. [DOI: 10.1007/s00384-019-03479-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
95 Lewis JD, Rutgeerts P, Feagan BG, D'haens G, Danese S, Colombel JF, Reinisch W, Rubin DT, Selinger C, Bewtra M, Barcomb L, Lacerda AP, Wallace K, Butler JW, Wu M, Zhou Q, Liao X, Sandborn WJ. Correlation of Stool Frequency and Abdominal Pain Measures With Simple Endoscopic Score for Crohn's Disease. Inflamm Bowel Dis 2020;26:304-13. [PMID: 31644790 DOI: 10.1093/ibd/izz241] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
96 Peltrini R, Greco PA, Manfreda A, Luglio G, Bucci L. Kono-S anastomosis after intestinal resection for Crohn’s disease. Updates Surg 2020;72:335-40. [DOI: 10.1007/s13304-019-00700-w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
97 Melendez-rosado J, Shen B. Endoscopic scores in inflammatory bowel disease. Atlas of Endoscopy Imaging in Inflammatory Bowel Disease 2020. [DOI: 10.1016/b978-0-12-814811-2.00014-1] [Reference Citation Analysis]
98 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020; 18: 2518-2525. e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]
99 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 727] [Cited by in F6Publishing: 763] [Article Influence: 242.3] [Reference Citation Analysis]
100 Sturm A, Maaser C, Calabrese E, Annese V, Fiorino G, Kucharzik T, Vavricka SR, Verstockt B, van Rheenen P, Tolan D, Taylor SA, Rimola J, Rieder F, Limdi JK, Laghi A, Krustiņš E, Kotze PG, Kopylov U, Katsanos K, Halligan S, Gordon H, González Lama Y, Ellul P, Eliakim R, Castiglione F, Burisch J, Borralho Nunes P, Bettenworth D, Baumgart DC, Stoker J; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. J Crohns Colitis 2019;13:273-84. [PMID: 30137278 DOI: 10.1093/ecco-jcc/jjy114] [Cited by in Crossref: 149] [Cited by in F6Publishing: 163] [Article Influence: 49.7] [Reference Citation Analysis]
101 Yzet C, Diouf M, Le Mouel JP, Brazier F, Turpin J, Loreau J, Dupas JL, Peyrin-Biroulet L, Fumery M. Complete Endoscopic Healing Associated With Better Outcomes Than Partial Endoscopic Healing in Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2020;18:2256-61. [PMID: 31743755 DOI: 10.1016/j.cgh.2019.11.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
102 Straksyte V, Kiudelis G, Gineikiene I, Janciauskas D, Basevicius A, Lukosevicius S, Kupcinskas L. Lemann Index for Assessment of Crohn's Disease: Correlation with the Quality of Life, Endoscopic Disease Activity, Magnetic Resonance Index of Activity and C- Reactive Protein. Open Med (Wars) 2019;14:785-91. [PMID: 31737782 DOI: 10.1515/med-2019-0092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
103 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Fecal Matrix Metalloprotease-9 and Lipocalin-2 as Biomarkers in Detecting Endoscopic Activity in Patients With Inflammatory Bowel Diseases. J Clin Gastroenterol 2018;52:e53-62. [PMID: 28723856 DOI: 10.1097/MCG.0000000000000837] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 8.3] [Reference Citation Analysis]
104 Mortensen JH, Lindholm M, Langholm LL, Kjeldsen J, Bay-Jensen AC, Karsdal MA, Manon-Jensen T. The intestinal tissue homeostasis - the role of extracellular matrix remodeling in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2019;13:977-93. [PMID: 31587588 DOI: 10.1080/17474124.2019.1673729] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
105 Subbotina OA, Letyagin AY, Rezakova MV. The Evolution of Biomarkers of Magnetic Resonance Enterography to Quantify Inflammation in Crohn's Disease. 2019 International Multi-Conference on Engineering, Computer and Information Sciences (SIBIRCON) 2019. [DOI: 10.1109/sibircon48586.2019.8958252] [Reference Citation Analysis]
106 Martin JC, Chang C, Boschetti G, Ungaro R, Giri M, Grout JA, Gettler K, Chuang LS, Nayar S, Greenstein AJ, Dubinsky M, Walker L, Leader A, Fine JS, Whitehurst CE, Mbow ML, Kugathasan S, Denson LA, Hyams JS, Friedman JR, Desai PT, Ko HM, Laface I, Akturk G, Schadt EE, Salmon H, Gnjatic S, Rahman AH, Merad M, Cho JH, Kenigsberg E. Single-Cell Analysis of Crohn's Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy. Cell 2019;178:1493-1508.e20. [PMID: 31474370 DOI: 10.1016/j.cell.2019.08.008] [Cited by in Crossref: 289] [Cited by in F6Publishing: 212] [Article Influence: 96.3] [Reference Citation Analysis]
107 Unger LW, Argeny S, Stift A, Yang Y, Karall A, Freilinger T, Müller C, Bergmann M, Stift J, Riss S. Mesenteric granulomas independently predict long-term risk of surgical recurrence in Crohn's disease. Colorectal Dis 2020;22:170-7. [PMID: 31393663 DOI: 10.1111/codi.14814] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
108 Peyrin-biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T. Anti-TNF biosimilars in Crohn’s Disease: a patient-centric interdisciplinary approach. Expert Review of Gastroenterology & Hepatology 2019;13:731-8. [DOI: 10.1080/17474124.2019.1645595] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
109 Wright EK, Ding NS, Niewiadomski O. Management of inflammatory bowel disease. Med J Aust 2018;209:318-23. [PMID: 30257634 DOI: 10.5694/mja17.01001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 32] [Article Influence: 9.0] [Reference Citation Analysis]
110 Heriot A, Smart P. Current Status of Segmental Colectomy in Select Crohn's Disease Patients. Clin Colon Rectal Surg 2019;32:249-54. [PMID: 31275070 DOI: 10.1055/s-0039-1683906] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
111 Deepak P, Axelrad JE, Ananthakrishnan AN. The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointestinal Endoscopy Clinics of North America 2019;29:447-70. [DOI: 10.1016/j.giec.2019.02.006] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
112 Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn's disease: what the clinician needs to know. Therap Adv Gastroenterol 2019;12:1756284819856865. [PMID: 31236140 DOI: 10.1177/1756284819856865] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 10.3] [Reference Citation Analysis]
113 Ciccocioppo R, Baumgart DC, Dos Santos CC, Galipeau J, Klersy C, Orlando G. Perspectives of the International Society for Cell & Gene Therapy Gastrointestinal Scientific Committee on the Intravenous Use of Mesenchymal Stromal Cells in Inflammatory Bowel Disease (PeMeGi). Cytotherapy 2019;21:824-39. [PMID: 31201092 DOI: 10.1016/j.jcyt.2019.05.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
114 Macaluso FS, Mocci G, Orlando A, Scondotto S, Fantaci G, Antonelli A, Leone S, Previtali E, Cabras F, Cottone M. Prevalence and incidence of inflammatory bowel disease in two Italian islands, Sicily and Sardinia: A report based on health information systems. Dig Liver Dis 2019;51:1270-4. [PMID: 31176630 DOI: 10.1016/j.dld.2019.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
115 Kang B, Choi SY, Choi YO, Lee SY, Baek SY, Sohn I, Choe BH, Lee HJ, Choe YH. Infliximab Trough Levels Are Associated With Mucosal Healing During Maintenance Treatment With Infliximab in Paediatric Crohn's Disease. J Crohns Colitis. 2019;13:189-197. [PMID: 30452616 DOI: 10.1093/ecco-jcc/jjy155] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
116 Argollo M, Gilardi D, Roda G, Fiorino G, Peyrin-biroulet L, Danese S. Anti-fibrotic Drugs for Crohn’s Disease: Ready for Prime Time? CPD 2019;25:47-56. [DOI: 10.2174/1381612825666190308100844] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
117 Sollelis E, Quinard RM, Bouguen G, Goutte M, Goutorbe F, Bouvier D, Pereira B, Bommelaer G, Buisson A. Combined evaluation of biomarkers as predictor of maintained remission in Crohn’s disease. World J Gastroenterol 2019; 25(19): 2354-2364 [PMID: 31148906 DOI: 10.3748/wjg.v25.i19.2354] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
118 Loy L, Roda G, Fiorino G, Allocca M, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. Detection and management of early stage inflammatory bowel disease: an update for clinicians. Expert Rev Gastroenterol Hepatol 2019;13:547-55. [PMID: 31007098 DOI: 10.1080/17474124.2019.1605291] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
119 Rao N, Kumar S, Taylor S, Plumb A. Diagnostic pathways in Crohn's disease. Clin Radiol 2019;74:578-91. [PMID: 31005268 DOI: 10.1016/j.crad.2019.03.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
120 Alfaro I, Masamunt MC, Planell N, López-García A, Castro J, Gallego M, Barastegui R, Giner A, Vara A, Salas A, Ricart E, Panés J, Ordás I. Endoscopic response to tumor necrosis factor inhibitors predicts long term benefits in Crohn’s disease. World J Gastroenterol 2019; 25(14): 1764-1774 [PMID: 31011260 DOI: 10.3748/wjg.v25.i14.1764] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
121 Koliani-Pace JL, Siegel CA. Prognosticating the Course of Inflammatory Bowel Disease. Gastrointest Endosc Clin N Am 2019;29:395-404. [PMID: 31078243 DOI: 10.1016/j.giec.2019.02.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
122 Pariente B, Hu S, Bettenworth D, Speca S, Desreumaux P, Meuwis M, Danese S, Rieder F, Louis E. Treatments for Crohn’s Disease–Associated Bowel Damage: A Systematic Review. Clinical Gastroenterology and Hepatology 2019;17:847-56. [DOI: 10.1016/j.cgh.2018.06.043] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 4.7] [Reference Citation Analysis]
123 Lerchova T, Hradsky O, Copova I, Potuznikova K, Gonsorcikova L, Bronsky J. The Accuracy of a Home-performed Faecal Calprotectin Test in Paediatric Patients With Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr 2019;69:75-81. [PMID: 30908389 DOI: 10.1097/MPG.0000000000002331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
124 Kato J, Yoshida T, Hiraoka S. Prediction of treatment outcome and relapse in inflammatory bowel disease. Expert Rev Clin Immunol 2019;15:667-77. [PMID: 30873890 DOI: 10.1080/1744666X.2019.1593140] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
125 Watanabe Y, Miyoshi N, Fujino S, Takahashi H, Haraguchi N, Hata T, Matsuda C, Yamamoto H, Doki Y, Mori M, Mizushima T. Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn's Disease. Dig Dis Sci. 2019;64:2280-2285. [PMID: 30806860 DOI: 10.1007/s10620-019-05553-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
126 Thierry ML, Rousseau H, Pouillon L, Girard-Gavanier M, Baumann C, Lopez A, Danese S, Laurent V, Peyrin-Biroulet L. Accuracy of Diffusion-weighted Magnetic Resonance Imaging in Detecting Mucosal Healing and Treatment Response, and in Predicting Surgery, in Crohn's Disease. J Crohns Colitis. 2018;12:1180-1190. [PMID: 29985999 DOI: 10.1093/ecco-jcc/jjy098] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
127 Minar P, Jackson K, Tsai YT, Sucharew H, Rosen MJ, Denson LA. Validation of Neutrophil CD64 Blood Biomarkers to Detect Mucosal Inflammation in Pediatric Crohn's Disease. Inflamm Bowel Dis 2017;24:198-208. [PMID: 29272485 DOI: 10.1093/ibd/izx022] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
128 White JR, Jairath V, Moran GW. Evolution of treatment targets in Crohn's disease. Best Pract Res Clin Gastroenterol 2019;38-39:101599. [PMID: 31327410 DOI: 10.1016/j.bpg.2019.02.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
129 Pai RK, Jairath V. What is the role of histopathology in the evaluation of disease activity in Crohn's disease? Best Pract Res Clin Gastroenterol 2019;38-39:101601. [PMID: 31327406 DOI: 10.1016/j.bpg.2019.02.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
130 Vande Casteele N, Sandborn WJ. Pharmacokinetics-Based Dosing for Therapeutic Monoclonal Antibodies in Inflammatory Bowel Disease. Quantitative Pharmacology and Individualized Therapy Strategies in Development of Therapeutic Proteins for Immune-Mediated Inflammatory Diseases 2019. [DOI: 10.1002/9781119289234.ch11] [Reference Citation Analysis]
131 Salameh E, Meleine M, Gourcerol G, do Rego JC, do Rego JL, Legrand R, Breton J, Aziz M, Guérin C, Coëffier M, Savoye G, Marion-Letellier R. Chronic colitis-induced visceral pain is associated with increased anxiety during quiescent phase. Am J Physiol Gastrointest Liver Physiol 2019;316:G692-700. [PMID: 30735453 DOI: 10.1152/ajpgi.00248.2018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 7.7] [Reference Citation Analysis]
132 Le Berre C, Danese S, Peyrin-biroulet L. Timely Use of Biologics in Early Crohn’s Disease: The Return of “Hit Hard and Early”? Dig Dis Sci 2019;64:3035-7. [DOI: 10.1007/s10620-019-05504-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
133 Kamperidis N, Middleton P, Tyrrell T, Stasinos I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol 2019;10:330-6. [PMID: 31682652 DOI: 10.1136/flgastro-2018-101024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
134 Pröbsting S, Terjung B. Neue medikamentöse Ansätze bei chronisch-entzündlichen Darmerkrankungen. coloproctology 2019;41:5-12. [DOI: 10.1007/s00053-018-0321-1] [Reference Citation Analysis]
135 Politis DS, Papamichael K, Katsanos KH, Koulouridis I, Mavromati D, Tsianos EV, Christodoulou DK. Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation. Ann Gastroenterol. 2019;32:168-173. [PMID: 30837789 DOI: 10.20524/aog.2019.0357] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
136 Allen PB, Peyrin-biroulet L. Disease Modification in Crohn’s Disease. Biomarkers in Inflammatory Bowel Diseases 2019. [DOI: 10.1007/978-3-030-11446-6_3] [Reference Citation Analysis]
137 Halfvarson J. Genetic Epidemiology of Inflammatory Bowel Disease, Early Twin and Family Studies. Molecular Genetics of Inflammatory Bowel Disease 2019. [DOI: 10.1007/978-3-030-28703-0_2] [Reference Citation Analysis]
138 Martin J, Boschetti G, Chang C, Ungaro R, Giri M, Chuang L, Nayar S, Greenstein A, Dubinsky M, Walker L, Leader A, Fine J, Whitehurst C, Mbow L, Kugathasan S, Denson L, Hyams J, Friedman J, Desai P, Ko H, Laface I, Akturk G, Schadt E, Gnjatic S, Rahman A, Merad M, Cho J, Kenigsberg E. Single-cell analysis of Crohn’s disease lesions identifies a pathogenic cellular module associated with resistance to anti-TNF therapy.. [DOI: 10.1101/503102] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
139 Terjung B, Gross M. Die aktuellen Studien zu Kolon, — Dünndarm und CED. Gastro-News 2018;5:52-57. [DOI: 10.1007/s15036-018-0507-y] [Reference Citation Analysis]
140 Yasin R, Kotkata SS, Goda W. Role of MR enterography in acute and chronic stages of Crohn's disease. The Egyptian Journal of Radiology and Nuclear Medicine 2018;49:953-8. [DOI: 10.1016/j.ejrnm.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Jones GR, Fascì-spurio F, Kennedy NA, Plevris N, Jenkinson P, Lyons M, Wong L, Maclean P, Glancy S, Lees CW. Faecal Calprotectin and Magnetic Resonance Enterography in Ileal Crohn’s Disease: Correlations Between Disease Activity and Long-Term Follow-Up. Journal of Crohn's and Colitis 2019;13:442-50. [DOI: 10.1093/ecco-jcc/jjy187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
142 Lenti MV, Di Sabatino A. Intestinal fibrosis. Mol Aspects Med 2019;65:100-9. [PMID: 30385174 DOI: 10.1016/j.mam.2018.10.003] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
143 Stevens TW, Matheeuwsen M, Lönnkvist MH, Parker CE, Wildenberg ME, Gecse KB, D’haens GR. Systematic review: predictive biomarkers of therapeutic response in inflammatory bowel disease-personalised medicine in its infancy. Aliment Pharmacol Ther 2018;48:1213-31. [DOI: 10.1111/apt.15033] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 6.5] [Reference Citation Analysis]
144 Serban ED. Treat-to-target in Crohn’s disease: Will transmural healing become a therapeutic endpoint? World J Clin Cases 2018; 6(12): 501-513 [PMID: 30397606 DOI: 10.12998/wjcc.v6.i12.501] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
145 Karolewska-Bochenek K, Grzesiowski P, Banaszkiewicz A, Gawronska A, Kotowska M, Dziekiewicz M, Albrecht P, Radzikowski A, Lazowska-Przeorek I. A Two-Week Fecal Microbiota Transplantation Course in Pediatric Patients with Inflammatory Bowel Disease. Adv Exp Med Biol. 2018;1047:81-87. [PMID: 29151253 DOI: 10.1007/5584_2017_123] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
146 Arieira C, Cúrdia Gonçaves T, Dias de Castro F, João Moreira M, Cotter J. Clinical course in Crohn’s disease: factors associated with behaviour change and surgery. Scandinavian Journal of Gastroenterology 2018;53:1222-7. [DOI: 10.1080/00365521.2018.1503709] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
147 Barat M, Hoeffel C, Bouquot M, Jannot AS, Dautry R, Boudiaf M, Pautrat K, Kaci R, Camus M, Eveno C, Pocard M, Soyer P, Dohan A. Preoperative evaluation of small bowel complications in Crohn’s disease: comparison of diffusion-weighted and contrast-enhanced MR imaging. Eur Radiol 2019;29:2034-44. [DOI: 10.1007/s00330-018-5734-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
148 Reinshagen M. Welche Patienten mit chronisch aktiver CED benötigen eine Biologikatherapie? CME 2018;15:59-66. [DOI: 10.1007/s11298-018-6508-5] [Reference Citation Analysis]
149 Nagata Y, Esaki M, Moriyama T, Hirano A, Umeno J, Maehata Y, Torisu T, Matsumoto T, Kitazono T. Anti-tumor necrosis factor therapy decreases the risk of initial intestinal surgery after diagnosis of Crohn's disease of inflammatory type. J Gastroenterol 2019;54:330-8. [PMID: 30244398 DOI: 10.1007/s00535-018-1511-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
150 Koliani-Pace JL, Siegel CA. Beyond disease activity to overall disease severity in inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2017;2:624-626. [PMID: 28786381 DOI: 10.1016/s2468-1253(17)30212-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
151 Pariente B, Blondeaux A. Editorial: paradoxical skin lesions during anti-TNF treatment-an additional argument to consider new biologics as first line therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2018;48:683-4. [PMID: 30132941 DOI: 10.1111/apt.14903] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Ma C, Jairath V, Khanna R, Feagan BG. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs 2018;27:649-60. [DOI: 10.1080/13543784.2018.1506764] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
153 Orlando S, Fraquelli M, Coletta M, Branchi F, Magarotto A, Conti CB, Mazza S, Conte D, Basilisco G, Caprioli F. Ultrasound Elasticity Imaging Predicts Therapeutic Outcomes of Patients With Crohn's Disease Treated With Anti-Tumour Necrosis Factor Antibodies. J Crohns Colitis 2018;12:63-70. [PMID: 28961950 DOI: 10.1093/ecco-jcc/jjx116] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
154 Wilkens R, Hagemann-Madsen RH, Peters DA, Nielsen AH, Nørager CB, Glerup H, Krogh K. Validity of Contrast-enhanced Ultrasonography and Dynamic Contrast-enhanced MR Enterography in the Assessment of Transmural Activity and Fibrosis in Crohn's Disease. J Crohns Colitis 2018;12:48-56. [PMID: 28981627 DOI: 10.1093/ecco-jcc/jjx111] [Cited by in Crossref: 63] [Cited by in F6Publishing: 65] [Article Influence: 15.8] [Reference Citation Analysis]
155 Weersma RK, Xavier RJ;  IBD Multi Omics Consortium; Vermeire S, Barrett JC. Multiomics Analyses to Deliver the Most Effective Treatment to Every Patient With Inflammatory Bowel Disease. Gastroenterology. 2018;155:e1-e4. [PMID: 30077628 DOI: 10.1053/j.gastro.2018.07.039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
156 Allocca M, Gilardi D, Fiorino G, Furfaro F, Argollo M, Peyrin-Biroulet L, Danese S. PF-00547659 for the treatment of Crohn's disease and ulcerative colitis. Expert Opin Investig Drugs 2018;27:623-9. [PMID: 29985060 DOI: 10.1080/13543784.2018.1494722] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
157 Qiu Y, Chen BL, Feng R, Zhang SH, He Y, Zeng ZR, Ben-Horin S, Peyrin-Biroulet L, Mao R, Chen MH. Prolonged azathioprine treatment reduces the need for surgery in early Crohn's disease. J Gastroenterol Hepatol 2018;33:664-70. [PMID: 28940780 DOI: 10.1111/jgh.14000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
158 Kim ES, Kim SK, Jang BI, Kim KO, Kim EY, Lee YJ, Lee HS, Kwak SG; Crohn’s and Colitis Association in Daegu-Gyeongbuk (CCAiD). Disease Activity Patterns Recorded Using a Mobile Monitoring System Are Associated with Clinical Outcomes of Patients with Crohn's Disease. Dig Dis Sci 2018;63:2220-30. [PMID: 29779084 DOI: 10.1007/s10620-018-5110-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
159 Liu W, Zhou W, Xiang J, Cao Q, Zhu J, Qi W, Chen P, Xie Q. Lémann Index at Diagnosis Predicts the Risk of Early Surgery in Crohn's Disease. Dis Colon Rectum 2018;61:207-13. [PMID: 29337776 DOI: 10.1097/DCR.0000000000000930] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
160 Villanueva Campos A, Tardáguila de la Fuente G, Utrera Pérez E, Jurado Basildo C, Mera Fernández D, Martínez Rodríguez C. Value of dual-energy CT enterography in the analysis of pathological bowel segments in patients with Crohn's disease. Radiología (English Edition) 2018;60:223-9. [DOI: 10.1016/j.rxeng.2018.03.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
161 Lee JM, Lee KM, Kim JS, Kim YS, Cheon JH, Ye BD, Kim YH, Han DS, Lee CK, Park HJ. Postoperative course of Crohn disease according to timing of bowel resection: Results from the CONNECT Study. Medicine (Baltimore) 2018;97:e0459. [PMID: 29668618 DOI: 10.1097/MD.0000000000010459] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
162 Kotze PG, Magro DO, Martinez CAR, Spinelli A, Yamamoto T, Warusavitarne J, Coy CSR. Long Time from Diagnosis to Surgery May Increase Postoperative Complication Rates in Elective CD Intestinal Resections: An Observational Study. Gastroenterol Res Pract 2018;2018:4703281. [PMID: 29849589 DOI: 10.1155/2018/4703281] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
163 Massinha P, Portela F, Campos S, Duque G, Ferreira M, Mendes S, Ferreira AM, Sofia C, Tomé L. Ulcerative Colitis: Are We Neglecting Its Progressive Character. GE Port J Gastroenterol 2018;25:74-9. [PMID: 29662931 DOI: 10.1159/000481263] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
164 Rozendorn N, Amitai MM, Eliakim RA, Kopylov U, Klang E. A review of magnetic resonance enterography-based indices for quantification of Crohn's disease inflammation. Therap Adv Gastroenterol 2018;11:1756284818765956. [PMID: 29686731 DOI: 10.1177/1756284818765956] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
165 Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG Clinical Guideline: Management of Crohn's Disease in Adults. Am J Gastroenterol. 2018;113:481-517. [PMID: 29610508 DOI: 10.1038/ajg.2018.27] [Cited by in Crossref: 586] [Cited by in F6Publishing: 609] [Article Influence: 146.5] [Reference Citation Analysis]
166 Villanueva Campos AM, Tardáguila de la Fuente G, Utrera Pérez E, Jurado Basildo C, Mera Fernández D, Martínez Rodríguez C. Value of dual-energy CT enterography in the analysis of pathological bowel segments in patients with Crohn's disease. Radiologia (Engl Ed) 2018;60:223-9. [PMID: 29549973 DOI: 10.1016/j.rx.2018.01.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
167 Ma C, Fedorak RN, Kaplan GG, Dieleman LA, Devlin SM, Stern N, Kroeker KI, Seow CH, Leung Y, Novak KL, Halloran BP, Huang VW, Wong K, Blustein PK, Ghosh S, Panaccione R. Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study. Inflamm Bowel Dis. 2017;23:833-839. [PMID: 28328624 DOI: 10.1097/mib.0000000000001074] [Cited by in Crossref: 63] [Cited by in F6Publishing: 66] [Article Influence: 15.8] [Reference Citation Analysis]
168 Laterza L, Piscaglia AC, Minordi LM, Scoleri I, Larosa L, Poscia A, Ingravalle F, Amato A, Alfieri S, Armuzzi A, Cammarota G, Gasbarrini A, Scaldaferri F. Multiparametric Evaluation Predicts Different Mid-Term Outcomes in Crohn's Disease. Dig Dis 2018;36:184-93. [PMID: 29514146 DOI: 10.1159/000487589] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
169 Lee KM. [Monitoring Disease Activity: How and When?]. Korean J Gastroenterol 2018;71:69-73. [PMID: 29471603 DOI: 10.4166/kjg.2018.71.2.69] [Reference Citation Analysis]
170 Li XH, Sun CH, Mao R, Huang SY, Zhang ZW, Yang XF, Huang L, Lin JJ, Zhang J, Ben-Horin S, Feng ST, Chen MH, Li ZP. Diffusion-weighted MRI Enables to Accurately Grade Inflammatory Activity in Patients of Ileocolonic Crohn's Disease: Results from an Observational Study. Inflamm Bowel Dis. 2017;23:244-253. [PMID: 28079618 DOI: 10.1097/mib.0000000000001001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
171 Rao BB, Click BH, Koutroubakis IE, Ramos Rivers C, Regueiro M, Swoger J, Schwartz M, Hashash J, Barrie A, Dunn MA, Binion DG. The Cost of Crohn's Disease: Varied Health Care Expenditure Patterns Across Distinct Disease Trajectories. Inflamm Bowel Dis 2017;23:107-15. [PMID: 27930405 DOI: 10.1097/MIB.0000000000000977] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
172 Deepak P, Fletcher JG, Fidler JL, Bruining DH. Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis. 2016;22:2280-2288. [PMID: 27508513 DOI: 10.1097/mib.0000000000000845] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
173 Messaris E. Digestive Tract Damage: A Predictor of Early Surgical Intervention in Patients With Newly Diagnosed Crohn’s Disease. Diseases of the Colon & Rectum 2018;61:147-148. [DOI: 10.1097/dcr.0000000000000931] [Reference Citation Analysis]
174 Reinshagen M. Welche Patienten mit chronisch aktiver CED benötigen eine Biologikatherapie? Gastro-News 2018;5:26-33. [DOI: 10.1007/s15036-018-0256-y] [Reference Citation Analysis]
175 Ripollés T, Paredes JM, Martínez-Pérez MJ, Rimola J, Jauregui-Amezaga A, Bouzas R, Martin G, Moreno-Osset E. Ultrasonographic Changes at 12 Weeks of Anti-TNF Drugs Predict 1-year Sonographic Response and Clinical Outcome in Crohn's Disease: A Multicenter Study. Inflamm Bowel Dis 2016;22:2465-73. [PMID: 27580385 DOI: 10.1097/MIB.0000000000000882] [Cited by in Crossref: 60] [Cited by in F6Publishing: 61] [Article Influence: 15.0] [Reference Citation Analysis]
176 Civitelli F, Nuti F, Oliva S, Messina L, La Torre G, Viola F, Cucchiara S, Aloi M. Looking Beyond Mucosal Healing: Effect of Biologic Therapy on Transmural Healing in Pediatric Crohn's Disease. Inflamm Bowel Dis 2016;22:2418-24. [PMID: 27598739 DOI: 10.1097/MIB.0000000000000897] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
177 Kotze PG, Magro DO, Saab B, Saab MP, Pinheiro LV, Olandoski M, Ayrizono MLS, Martinez CAR, Coy CSR. Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. Intest Res. 2018;16:62-68. [PMID: 29422799 DOI: 10.5217/ir.2018.16.1.62] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
178 Fernandes SR, Pinto JSLD, Marques da Costa P, Correia L; GEDII. Disagreement Among Gastroenterologists Using the Mayo and Rutgeerts Endoscopic Scores. Inflammatory Bowel Diseases 2018;24:254-60. [DOI: 10.1093/ibd/izx066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
179 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
180 Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA; Society of Abdominal Radiology Crohn’s Disease-Focused Panel. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Radiology 2018;286:776-99. [PMID: 29319414 DOI: 10.1148/radiol.2018171737] [Cited by in Crossref: 120] [Cited by in F6Publishing: 126] [Article Influence: 30.0] [Reference Citation Analysis]
181 Bruining DH, Zimmermann EM, Loftus EV Jr, Sandborn WJ, Sauer CG, Strong SA; Society of Abdominal Radiology Crohn’s Disease-Focused Panel. Consensus Recommendations for Evaluation, Interpretation, and Utilization of Computed Tomography and Magnetic Resonance Enterography in Patients With Small Bowel Crohn's Disease. Gastroenterology 2018;154:1172-94. [PMID: 29329905 DOI: 10.1053/j.gastro.2017.11.274] [Cited by in Crossref: 107] [Cited by in F6Publishing: 113] [Article Influence: 26.8] [Reference Citation Analysis]
182 Wils P, Bouhnik Y, Michetti P, Flourie B, Brixi H, Bourrier A, Allez M, Duclos B, Serrero M, Buisson A, Amiot A, Fumery M, Roblin X, Peyrin-biroulet L, Filippi J, Bouguen G, Abitbol V, Coffin B, Simon M, Laharie D, Pariente B; Groupe d'Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience. Aliment Pharmacol Ther 2018;47:588-95. [DOI: 10.1111/apt.14487] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 13.3] [Reference Citation Analysis]
183 Watanabe K, Kamata N, Hosomi S, Suekane T, Sano K, Yukawa T, Yamagami H, Fujiwara Y, Nebiki H, Arakawa T. The Efficacies and Issues for Endoscopic Assessment of Mucosal Healing in Patients with Crohn’s Disease. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_19] [Reference Citation Analysis]
184 Rogler G. Challenges of Translation of Anti-Fibrotic Therapies into Clinical Practice in IBD. Fibrostenotic Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-3-319-90578-5_20] [Reference Citation Analysis]
185 Fujii T. Current Progress of Endoscopy in Inflammatory Bowel Disease: MR Enterography. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_6] [Reference Citation Analysis]
186 Ohtsuka K. Difficulty in Diagnosing Inflammatory Bowel Disease: A Case Study. Advances in Endoscopy in Inflammatory Bowel Disease 2018. [DOI: 10.1007/978-4-431-56018-0_14] [Reference Citation Analysis]
187 Deepak P, Sheedy SP, Lightner AL, Bruining DH. Role of Abdominal Imaging in the Diagnosis of IBD Strictures, Fistulas, and Postoperative Complications. Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications 2018. [DOI: 10.1016/b978-0-12-811388-2.00007-5] [Reference Citation Analysis]
188 Fricker J. Keep Calm and Treat to Target in Inflammatory Bowel Disease. EMJ Gastroenterol 2017. [DOI: 10.33590/emjgastroenterol/10311358] [Reference Citation Analysis]
189 Spekhorst LM, Oldenburg B, van Bodegraven AA, de Jong DJ, Imhann F, van der Meulen-de Jong AE, Pierik MJ, van der Woude JC, Dijkstra G, D’Haens G, Löwenberg M, Weersma RK, Festen EAM, Parelsnoer Institute and the Dutch Initiative on Crohn and Colitis. Prevalence of- and risk factors for work disability in Dutch patients with inflammatory bowel disease. World J Gastroenterol 2017; 23(46): 8182-8192 [PMID: 29290654 DOI: 10.3748/wjg.v23.i46.8182] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
190 Hanauer SB. Targeting Crohn's disease. The Lancet 2017;390:2742-2744. [DOI: 10.1016/s0140-6736(17)32754-x] [Reference Citation Analysis]
191 Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut 2017;66:2179-87. [PMID: 28874419 DOI: 10.1136/gutjnl-2017-314519] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 12.8] [Reference Citation Analysis]
192 Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, Laurent V, Zallot C, Peyrin-Biroulet L, Danese S. Prevalence of Bowel Damage Assessed by Cross-Sectional Imaging in Early Crohn's Disease and its Impact on Disease Outcome. J Crohns Colitis. 2017;11:274-280. [PMID: 27799269 DOI: 10.1093/ecco-jcc/jjw185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
193 Novak KL, Kaplan GG, Panaccione R, Afshar EE, Tanyingoh D, Swain M, Kellar A, Wilson S. A Simple Ultrasound Score for the Accurate Detection of Inflammatory Activity in Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:2001-10. [DOI: 10.1097/mib.0000000000001174] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 8.6] [Reference Citation Analysis]
194 Begun J. Inflammatory bowel disease in the clinic: Escalation and de-escalation of therapy: A longitudinal case-based discussion. J Gastroenterol Hepatol 2016;31 Suppl 1:12-3. [PMID: 26990807 DOI: 10.1111/jgh.13348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Baldwin KR, Kaplan JL. Medical management of pediatric inflammatory bowel disease. Semin Pediatr Surg 2017;26:360-6. [PMID: 29126504 DOI: 10.1053/j.sempedsurg.2017.10.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
196 Seo H, Ye BD, Song EM, Lee S, Chang K, Lee H, Hwang SW, Park SH, Yang D, Kim K, Byeon J, Myung S, Yang S. Long-Term Outcomes of Adalimumab Treatment in 254 Patients with Crohn’s Disease: A Hospital-Based Cohort Study from Korea. Dig Dis Sci 2017;62:2882-93. [DOI: 10.1007/s10620-017-4715-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
197 Kopylov U, Koulaouzidis A, Klang E, Carter D, Ben-Horin S, Eliakim R. Monitoring of small bowel Crohn's disease. Expert Rev Gastroenterol Hepatol 2017;11:1047-58. [PMID: 28737951 DOI: 10.1080/17474124.2017.1359541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
198 Bamba S, Sasaki M, Takaoka A, Takahashi K, Imaeda H, Nishida A, Inatomi O, Sugimoto M, Andoh A. Sarcopenia is a predictive factor for intestinal resection in admitted patients with Crohn's disease. PLoS One. 2017;12:e0180036. [PMID: 28644887 DOI: 10.1371/journal.pone.0180036] [Cited by in Crossref: 62] [Cited by in F6Publishing: 63] [Article Influence: 12.4] [Reference Citation Analysis]
199 Oh K, Oh EH, Baek S, Song EM, Kim GU, Seo M, Hwang SW, Park SH, Yang DH, Kim KJ, Byeon JS, Myung SJ, Yang SK, Ye BD. Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn's disease. PLoS One. 2017;12:e0179266. [PMID: 28622356 DOI: 10.1371/journal.pone.0179266] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
200 Ikeshima R, Mizushima T, Takahashi H, Haraguchi N, Nishimura J, Hata T, Matsuda C, Ikenaga M, Nakajima K, Yamamoto H, Murata K, Doki Y, Mori M. The efficacy of active drainage for preventing postoperative organ/space surgical site infections in patients with Crohn's disease. Surg Today 2018;48:25-32. [PMID: 28608250 DOI: 10.1007/s00595-017-1549-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
201 Huang L, Li X, Huang S, Zhang Z, Yang X, Lin J, Jiang M, Feng S, Sun C, Li Z. Diffusion kurtosis MRI versus conventional diffusion-weighted imaging for evaluating inflammatory activity in Crohn's disease: CD Activity Assessment Using DKI. J Magn Reson Imaging 2018;47:702-9. [DOI: 10.1002/jmri.25768] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
202 Panés J, Sandborn WJ, Schreiber S, Sands BE, Vermeire S, D'Haens G, Panaccione R, Higgins PDR, Colombel JF, Feagan BG, Chan G, Moscariello M, Wang W, Niezychowski W, Marren A, Healey P, Maller E. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials. Gut 2017;66:1049-59. [PMID: 28209624 DOI: 10.1136/gutjnl-2016-312735] [Cited by in Crossref: 212] [Cited by in F6Publishing: 216] [Article Influence: 42.4] [Reference Citation Analysis]
203 Ye L, Cheng W, Chen BQ, Lan X, Wang SD, Wu XC, Huang W, Wang FY. Levels of Faecal Calprotectin and Magnetic Resonance Enterocolonography Correlate with Severity of Small Bowel Crohn's Disease: A Retrospective Cohort Study. Sci Rep 2017;7:1970. [PMID: 28512287 DOI: 10.1038/s41598-017-02111-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
204 Fricker J. Targeting Disease Progression in Crohn’s Disease: Fighting an Unrelenting Enemy. EMJ Gastroenterol 2017. [DOI: 10.33590/emjgastroenterol/10311106] [Reference Citation Analysis]
205 Sánchez-martínez M, Garcia-planella E, Laiz A, Puig L. Enfermedad inflamatoria intestinal: abordaje conjunto digestivo-dermatológico. Actas Dermo-Sifiliográficas 2017;108:184-191. [DOI: 10.1016/j.ad.2016.07.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
206 Sánchez-martínez M, Garcia-planella E, Laiz A, Puig L. Inflammatory Bowel Disease: Joint Management in Gastroenterology and Dermatology. Actas Dermo-Sifiliográficas (English Edition) 2017;108:184-191. [DOI: 10.1016/j.adengl.2017.02.011] [Reference Citation Analysis]
207 Kim S. Surgery in Pediatric Crohn's Disease: Indications, Timing and Post-Operative Management. Pediatr Gastroenterol Hepatol Nutr 2017;20:14-21. [PMID: 28401051 DOI: 10.5223/pghn.2017.20.1.14] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
208 Allen PB, Olivera P, Emery P, Moulin D, Jouzeau J, Netter P, Danese S, Feagan B, Sandborn WJ, Peyrin-biroulet L. Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritis. Aliment Pharmacol Ther 2017;45:1058-72. [DOI: 10.1111/apt.13995] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 7.6] [Reference Citation Analysis]
209 Amitai MM, Zarchin M, Lahat A, Yablecovitch D, Neuman S, Levhar N, Klang E, Avidan B, Ben-Horin S, Eliakim R, Kopylov U; Israeli IBD research Nucleus (IIRN). Structural bowel damage in quiescent Crohn's disease. Dig Liver Dis. 2017;49:490-494. [PMID: 28233685 DOI: 10.1016/j.dld.2017.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
210 Hirschmann S, Neurath MF. Top-down approach to biological therapy of Crohn's disease. Expert Opin Biol Ther 2017;17:285-93. [PMID: 28132526 DOI: 10.1080/14712598.2017.1287170] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
211 Magro F, Dias CC, Coelho R, Santos PM, Fernandes S, Caetano C, Rodrigues Â, Portela F, Oliveira A, Ministro P, Cancela E, Vieira AI, Barosa R, Cotter J, Carvalho P, Cremers I, Trabulo D, Caldeira P, Antunes A, Rosa I, Moleiro J, Peixe P, Herculano R, Gonçalves R, Gonçalves B, Tavares Sousa H, Contente L, Morna H, Lopes S. Impact of Early Surgery and Immunosuppression on Crohnʼs Disease Disabling Outcomes: . Inflammatory Bowel Diseases 2017;23:289-97. [DOI: 10.1097/mib.0000000000001007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
212 Marion-Letellier R, Bohn P, Modzelewski R, Vera P, Aziz M, Guérin C, Savoye G, Savoye-Collet C. SPECT-computed tomography in rats with TNBS-induced colitis: A first step toward functional imaging. World J Gastroenterol 2017; 23(2): 216-223 [PMID: 28127195 DOI: 10.3748/wjg.v23.i2.216] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
213 Mocci G, Migaleddu V, Cabras F, Sirigu D, Scanu D, Virgilio G, Marzo M. SICUS and CEUS imaging in Crohn's disease: an update. J Ultrasound 2017;20:1-9. [PMID: 28298939 DOI: 10.1007/s40477-016-0230-5] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 5.2] [Reference Citation Analysis]
214 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnosis and treatment of inflammatory bowel disease: First Latin American Consensus of the Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México (English Edition) 2017;82:46-84. [DOI: 10.1016/j.rgmxen.2016.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
215 Rogalla P, Guimarães L. Magnetic Resonance Enterography. Crohn's Disease and Ulcerative Colitis 2017. [DOI: 10.1007/978-3-319-33703-6_18] [Reference Citation Analysis]
216 González-lama Y, Sanz J, Bastida G, Campos J, Ferreiro R, Joven B, Gutiérrez A, Juanola X, Sicilia B, Veroz R, Gisbert J, Chaparro M, Domènech E, Esteve M, Gomollón F. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con espondiloartritis asociada a enfermedad inflamatoria intestinal. Enfermedad Inflamatoria Intestinal al Día 2017;16:1-14. [DOI: 10.1016/j.eii.2016.09.002] [Reference Citation Analysis]
217 Yamamoto-furusho J, Bosques-padilla F, de-Paula J, Galiano M, Ibañez P, Juliao F, Kotze P, Rocha J, Steinwurz F, Veitia G, Zaltman C. Diagnóstico y tratamiento de la enfermedad inflamatoria intestinal: Primer Consenso Latinoamericano de la Pan American Crohn's and Colitis Organisation. Revista de Gastroenterología de México 2017;82:46-84. [DOI: 10.1016/j.rgmx.2016.07.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
218 Turner D, Ledder O. Clinical Indices for Pediatric Inflammatory Bowel Disease Research. Pediatric Inflammatory Bowel Disease 2017. [DOI: 10.1007/978-3-319-49215-5_46] [Reference Citation Analysis]
219 Yamamoto T, Shimoyama T, Umegae S. The Cutting Edge of Intestinal Surgery for Crohn's Disease: a Multidisciplinary Team Approach. Journal of Japan Society of Coloproctology 2017;70:611-622. [DOI: 10.3862/jcoloproctology.70.611] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
220 Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389:1741-1755. [PMID: 27914655 DOI: 10.1016/s0140-6736(16)31711-1] [Cited by in Crossref: 955] [Cited by in F6Publishing: 999] [Article Influence: 159.2] [Reference Citation Analysis]
221 Kucharzik T, Wittig BM, Helwig U, Börner N, Rössler A, Rath S, Maaser C; TRUST study group. Use of Intestinal Ultrasound to Monitor Crohn's Disease Activity. Clin Gastroenterol Hepatol 2017;15:535-542.e2. [PMID: 27856365 DOI: 10.1016/j.cgh.2016.10.040] [Cited by in Crossref: 114] [Cited by in F6Publishing: 115] [Article Influence: 19.0] [Reference Citation Analysis]
222 Molander P, Färkkilä M, Kemppainen H, Blomster T, Jussila A, Mustonen H, Sipponen T. Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFα-blocking agents. Scandinavian Journal of Gastroenterology 2017;52:284-90. [DOI: 10.1080/00365521.2016.1250942] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
223 Bodini G, Giannini EG, De Maria C, Dulbecco P, Furnari M, Marabotto E, Savarino V, Savarino E. Anti-TNF therapy is able to stabilize bowel damage progression in patients with Crohn's disease. A study performed using the Lémann Index. Dig Liver Dis 2017;49:175-80. [PMID: 27864028 DOI: 10.1016/j.dld.2016.10.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
224 Limketkai BN, Orandi BJ, Luo X, Segev DL, Colombel J. Mortality and Rates of Graft Rejection or Failure Following Intestinal Transplantation in Patients With vs Without Crohn’s Disease. Clinical Gastroenterology and Hepatology 2016;14:1574-81. [DOI: 10.1016/j.cgh.2016.06.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
225 DeFilippis EM, Longman R, Harbus M, Dannenberg K, Scherl EJ. Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies. Curr Gastroenterol Rep 2016;18:13. [PMID: 26908281 DOI: 10.1007/s11894-016-0487-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
226 Panes J, Jairath V, Levesque BG. Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases. Gastroenterology. 2017;152:362-373.e3. [PMID: 27751880 DOI: 10.1053/j.gastro.2016.10.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 9.2] [Reference Citation Analysis]
227 Baidoo L, Hanauer SB. What Is the Best Approach to Avoid Colorectal Cancer Risk in Inflammatory Bowel Disease? Curr Colorectal Cancer Rep 2016;12:345-51. [DOI: 10.1007/s11888-016-0339-0] [Reference Citation Analysis]
228 Luján-Sanchis M, Sanchis-Artero L, Larrey-Ruiz L, Peño-Muñoz L, Núñez-Martínez P, Castillo-López G, González-González L, Clemente CB, Albert Antequera C, Durá-Ayet A, Sempere-Garcia-Argüelles J. Current role of capsule endoscopy in Crohn’s disease. World J Gastrointest Endosc 2016; 8(17): 572-583 [PMID: 27668067 DOI: 10.4253/wjge.v8.i17.572] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
229 Magarotto A, Orlando S, Coletta M, Conte D, Fraquelli M, Caprioli F. Evolving roles of cross-sectional imaging in Crohn's disease. Digestive and Liver Disease 2016;48:975-83. [DOI: 10.1016/j.dld.2016.05.017] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
230 Jairath V, Levesque BG, Vande Casteele N, Khanna R, Mosli M, Hindryckx P, Travis S, Duijvenstein M, Rimola J, Panes J, D’haens G, Sandborn WJ, Feagan BG. Evolving Concepts in Phases I and II Drug Development for Crohn’s Disease. ECCOJC 2017;11:246-55. [DOI: 10.1093/ecco-jcc/jjw137] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
231 Takeshima F, Yoshikawa D, Higashi S, Morisaki T, Oda H, Ikeda M, Machida H, Matsushima K, Minami H, Akazawa Y, Yamaguchi N, Ohnita K, Isomoto H, Ueno M, Nakao K. Clinical efficacy of adalimumab in Crohn's disease: a real practice observational study in Japan. BMC Gastroenterol 2016;16:82. [PMID: 27472988 DOI: 10.1186/s12876-016-0501-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
232 Suzuki K, Arumugam S, Yokoyama J, Kawauchi Y, Honda Y, Sato H, Aoyagi Y, Terai S, Okazaki K, Suzuki Y, Mizumoto S, Sugahara K, Atreya R, Neurath MF, Watanabe K, Hashiguchi T, Yoneyama H, Asakura H. Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One 2016;11:e0158967. [PMID: 27410685 DOI: 10.1371/journal.pone.0158967] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
233 Bayart P, Duveau N, Nachury M, Zerbib P, Gerard R, Branche J, Maunoury V, Wils P, Boruchowicz A, Boualit M, Laberenne J, Manolache O, Desreumaux P, de Chambrun GP, Pariente B. Ileal or Anastomotic Location of Lesions Does Not Impact Rate of Postoperative Recurrence in Crohn’s Disease Patients Classified i2 on the Rutgeerts Score. Dig Dis Sci 2016;61:2986-92. [DOI: 10.1007/s10620-016-4215-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
234 Bhagya Rao B, Koutroubakis IE, Ramos Rivers C, Colombel JF, Regueiro M, Swoger J, Schwartz M, Baidoo L, Hashash J, Barrie A, Dunn MA, Binion DG. Delineation of Crohn’s Disease Trajectories Using Change in Lémann Index: A Natural History Study. Journal of Clinical Gastroenterology 2016;50:476-82. [DOI: 10.1097/mcg.0000000000000463] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
235 Keihanian S, Moss AC. Crohn’s disease stricture evaluation and management. Techniques in Gastrointestinal Endoscopy 2016;18:136-144. [DOI: 10.1016/j.tgie.2016.08.004] [Reference Citation Analysis]
236 Alrubaiy L, Rikaby I, Sageer M, Hutchings HA, Williams JG. Systematic Review of the Clinical Disease Severity Indices for Inflammatory Bowel Disease. Inflamm Bowel Dis 2015;21:2460-6. [PMID: 25966838 DOI: 10.1097/MIB.0000000000000438] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
237 O’malley RB, Hansen NJ, Carnell J, Afzali A, Moshiri M. Update on MR Enterography: Potentials and Pitfalls. Curr Radiol Rep 2016;4. [DOI: 10.1007/s40134-016-0172-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
238 Boucher AL, Pereira B, Decousus S, Goutte M, Goutorbe F, Dubois A, Gagniere J, Borderon C, Joubert J, Pezet D, Dapoigny M, Déchelotte PJ, Bommelaer G, Buisson A. Endoscopy-based management decreases the risk of postoperative recurrences in Crohn’s disease. World J Gastroenterol 2016; 22(21): 5068-5078 [PMID: 27275099 DOI: 10.3748/wjg.v22.i21.5068] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
239 Onal IK, Beyazit Y, Altinbas A, Kurt M, Arhan M. Maintenance therapy for Crohn's disease: should it be indefinite? Eur J Gastroenterol Hepatol. 2015; Jul 15. [Epub ahead of print]. [PMID: 26181109 DOI: 10.1097/MEG.0000000000000433] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
240 Chapman CG, Yamaguchi R, Tamura K, Weidner J, Imoto S, Kwon J, Fang H, Yew PY, Marino SR, Miyano S, Nakamura Y, Kiyotani K. Characterization of T-cell Receptor Repertoire in Inflamed Tissues of Patients with Crohnʼs Disease Through Deep Sequencing: . Inflammatory Bowel Diseases 2016;22:1275-85. [DOI: 10.1097/mib.0000000000000752] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
241 Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Fujioka T, Matsuoka K, Naganuma M, Watanabe M. Correlation of the Endoscopic and Magnetic Resonance Scoring Systems in the Deep Small Intestine in Crohn’s Disease. Inflamm Bowel Dis. 2015;21:1832-1838. [PMID: 26020602 DOI: 10.1097/mib.0000000000000449] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 6.5] [Reference Citation Analysis]
242 Marchioni Beery RM, Korzenik JR. Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way? J Clin Gastroenterol 2016;50:441-4. [PMID: 27159423 DOI: 10.1097/MCG.0000000000000539] [Reference Citation Analysis]
243 Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, Bristogiannis C, Stoppino G, Vinci R, Macarini L. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging 2016;16:37. [PMID: 27149857 DOI: 10.1186/s12880-016-0139-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 5.2] [Reference Citation Analysis]
244 Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ, Loftus EV Jr. Cumulative Length of Bowel Resection in a Population-Based Cohort of Patients With Crohn's Disease. Clin Gastroenterol Hepatol 2016;14:1439-44. [PMID: 27155552 DOI: 10.1016/j.cgh.2016.04.031] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
245 Bharadwaj S, Fleshner P, Shen B. Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. Inflamm Bowel Dis 2015;21:2194-213. [PMID: 25985249 DOI: 10.1097/MIB.0000000000000403] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 9.0] [Reference Citation Analysis]
246 Inokuchi T, Kato J, Hiraoka S, Takashima S, Nakarai A, Takei D, Sugihara Y, Takahara M, Kawano S, Harada K, Okada H. Fecal Immunochemical Test Versus Fecal Calprotectin for Prediction of Mucosal Healing in Crohnʼs Disease: . Inflammatory Bowel Diseases 2016;22:1078-85. [DOI: 10.1097/mib.0000000000000728] [Cited by in Crossref: 39] [Cited by in F6Publishing: 42] [Article Influence: 6.5] [Reference Citation Analysis]
247 Ahmed O, Rodrigues DM, Nguyen GC. Magnetic Resonance Imaging of the Small Bowel in Crohn's Disease: A Systematic Review and Meta-Analysis. Can J Gastroenterol Hepatol 2016;2016:7857352. [PMID: 27446869 DOI: 10.1155/2016/7857352] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
248 (Masahito Tachi) 館正, (Hisaaki Kato) 加久, (Yoshito Tanaka) 田義, (Takahito Miyake) 三喬, (Shiho Nakano) 中志, (Kazuhiro Yoshida) 吉和, (Shinji Ogura) 小真. 大腸Crohn病の後腹膜穿通により骨盤腔から下肢に至る広範囲膿瘍を形成した1例(A case of Crohn’s disease complicated by a diffuse abscess extending from the retroperitoneum to the left crus). Nihon Kyukyu Igakukai Zasshi: Japanese Journal of Japanese Association for Acute Medicine 2016;27:130-136. [DOI: 10.1002/jja2.12094] [Reference Citation Analysis]
249 Caccaro R, Angriman I, D’Incà R. Relevance of fecal calprotectin and lactoferrin in the post-operative management of inflammatory bowel diseases. World J Gastrointest Surg 2016; 8(3): 193-201 [PMID: 27022446 DOI: 10.4240/wjgs.v8.i3.193] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
250 Bruining DH, Bhatnagar G, Rimola J, Taylor S, Zimmermann EM, Fletcher JG. CT and MR enterography in Crohn's disease: current and future applications. Abdom Imaging 2015;40:965-74. [PMID: 25637127 DOI: 10.1007/s00261-015-0360-9] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
251 Ogata H, Watanabe M, Matsui T, Hase H, Okayasu M, Tsuchiya T, Shinmura Y, Hibi T. Safety of Adalimumab and Predictors of Adverse Events in 1693 Japanese Patients with Crohn's Disease. J Crohns Colitis 2016;10:1033-41. [PMID: 26961546 DOI: 10.1093/ecco-jcc/jjw060] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
252 Buisson A, Vazeille E, Minet-Quinard R, Goutte M, Bouvier D, Goutorbe F, Pereira B, Barnich N, Bommelaer G. Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2016;43:1069-1079. [PMID: 26953251 DOI: 10.1111/apt.13585] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
253 Decousus S, Boucher AL, Joubert J, Pereira B, Dubois A, Goutorbe F, Déchelotte PJ, Bommelaer G, Buisson A. Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn's disease. Dig Liver Dis 2016;48:753-8. [PMID: 27005857 DOI: 10.1016/j.dld.2016.02.023] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
254 Bhagya Rao B, Koutroubakis IE, Rivers CR, Regueiro M, Swoger J, Schwartz M, Baidoo L, Hashash J, Barrie A, Dunn MA, Binion DG. Correlation of anemia status with worsening bowel damage as measured by Lémann Index in patients with Crohn's disease. Dig Liver Dis 2016;48:626-31. [PMID: 27005859 DOI: 10.1016/j.dld.2016.02.020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
255 Buisson A, Hordonneau C, Goutte M, Scanzi J, Goutorbe F, Klotz T, Boyer L, Pereira B, Bommelaer G. Diffusion-weighted magnetic resonance enterocolonography in predicting remission after anti-TNF induction therapy in Crohn's disease. Digestive and Liver Disease 2016;48:260-6. [DOI: 10.1016/j.dld.2015.10.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
256 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 133] [Cited by in F6Publishing: 136] [Article Influence: 22.2] [Reference Citation Analysis]
257 Westerland O, Griffin N. Magnetic Resonance Enterography in Crohn׳s Disease. Semin Ultrasound CT MR 2016;37:282-91. [PMID: 27342892 DOI: 10.1053/j.sult.2016.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
258 Cintolo M, Costantino G, Pallio S, Fries W. Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol 2016; 7(1): 1-16 [PMID: 26909224 DOI: 10.4291/wjgp.v7.i1.1] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
259 Leitner GC, Vogelsang H. Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther 2016; 7(1): 5-20 [PMID: 26855808 DOI: 10.4292/wjgpt.v7.i1.5] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
260 Reenaers C, Pirard C, Vankemseke C, Latour P, Belaiche J, Louis E. Long-term evolution and predictive factors of mild inflammatory bowel disease. Scand J Gastroenterol 2016;51:712-9. [PMID: 26815198 DOI: 10.3109/00365521.2015.1128965] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
261 Kilcoyne A, Kaplan JL, Gee MS. Inflammatory bowel disease imaging: Current practice and future directions. World J Gastroenterol 2016; 22(3): 917-932 [PMID: 26811637 DOI: 10.3748/wjg.v22.i3.917] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 69] [Article Influence: 11.5] [Reference Citation Analysis]
262 Fiorino G, Bonifacio C, Peyrin-Biroulet L, Danese S. Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis 2016;10:495-500. [PMID: 26744441 DOI: 10.1093/ecco-jcc/jjv240] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
263 Mazza M, Cilluffo MG, Cappello M. Clinical Presentation of Crohn’s Disease. Crohn’s Disease 2016. [DOI: 10.1007/978-3-319-23066-5_2] [Reference Citation Analysis]
264 Nakamura M, Hirooka Y, Watanabe O, Yamamura T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Goto H. A Retrospective Evaluation of the Utility of Capsule Endoscopy and Double-Balloon Endoscopy in Crohn's Disease. Gastroenterol Res Pract 2016;2016:1085027. [PMID: 26843856 DOI: 10.1155/2016/1085027] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
265 Falvey JD, Hoskin T, Meijer B, Ashcroft A, Walmsley R, Day AS, Gearry RB. Disease activity assessment in IBD: clinical indices and biomarkers fail to predict endoscopic remission. Inflamm Bowel Dis. 2015;21:824-831. [PMID: 25738372 DOI: 10.1097/mib.0000000000000341] [Cited by in Crossref: 96] [Cited by in F6Publishing: 102] [Article Influence: 13.7] [Reference Citation Analysis]
266 Murphy D, Smyth A, Mcevoy S, Gibson D, Doherty G, Malone D. Subclassification of small bowel Crohn's disease using magnetic resonance enterography: a review using evidence-based medicine methodology. Clinical Radiology 2015;70:1336-43. [DOI: 10.1016/j.crad.2015.07.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
267 Melmed GY, Targan SR. Crohn's Disease: Clinical Manifestations and Management. Yamada' s Textbook of Gastroenterology 2015. [DOI: 10.1002/9781118512074.ch72] [Reference Citation Analysis]
268 Iannicelli E, Martini I, Fantini C, Papi C, Gigante P, Carbonetti F, Di Pietropaolo M, David V. Magnetic resonance enterography in Crohn's disease: new simple proposal to assess disease activity. Clin Imaging. 2016;40:492-497. [PMID: 27133693 DOI: 10.1016/j.clinimag.2015.11.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
269 Scardapane A, Ambrosi A, Salinaro E, Mancini ME, Principi M, Di Leo A, Lorusso F, Stabile Ianora AA, Angelelli G. Assessment of Disease Activity in Small Bowel Crohn's Disease: Comparison between Endoscopy and Magnetic Resonance Enterography Using MRIA and Modified MRIA Score. Gastroenterol Res Pract 2015;2015:159641. [PMID: 26759554 DOI: 10.1155/2015/159641] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
270 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
271 González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. J Crohns Colitis 2016;10:55-60. [PMID: 26520164 DOI: 10.1093/ecco-jcc/jjv187] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
272 Qiu Y, Chen BL, Mao R, Zhang SH, He Y, Zeng ZR, Chen MH. Early Thiopurines Versus Conventional Step-Care Therapy for Modifying the Disease Course of Early Crohn's Disease: A Tertiary Referral Center Cohort Study. Medicine (Baltimore) 2015;94:e1148. [PMID: 26252273 DOI: 10.1097/MD.0000000000001148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
273 Fumery M, Pineton de Chambrun G, Stefanescu C, Buisson A, Bressenot A, Beaugerie L, Amiot A, Altwegg R, Savoye G, Abitbol V, Bouguen G, Simon M, Duffas J, Hébuterne X, Nancey S, Roblin X, Leteurtre E, Bommelaer G, Lefevre JH, Brunetti F, Guillon F, Bouhnik Y, Peyrin-biroulet L. Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures. Clinical Gastroenterology and Hepatology 2015;13:1770-5. [DOI: 10.1016/j.cgh.2015.04.185] [Cited by in Crossref: 64] [Cited by in F6Publishing: 53] [Article Influence: 9.1] [Reference Citation Analysis]
274 Lee SM, Kim WS, Choi YH. Pediatric Magnetic Resonance Enterography: Focused on Crohn’s Disease. Pediatr Gastroenterol Hepatol Nutr. 2015;18:149-159. [PMID: 26473134 DOI: 10.5223/pghn.2015.18.3.149] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
275 Bryant RV, Brain O, Travis SP. Conventional drug therapy for inflammatory bowel disease. Scand J Gastroenterol. 2015;50:90-112. [PMID: 25523560 DOI: 10.3109/00365521.2014.968864] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 6.7] [Reference Citation Analysis]
276 Rimola J, Panés J, Ordás I. Magnetic resonance enterography in Crohn's disease: optimal use in clinical practice and clinical trials. Scand J Gastroenterol 2015;50:66-73. [PMID: 25523557 DOI: 10.3109/00365521.2014.968862] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
277 Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015;149:1716-1730. [PMID: 26381892 DOI: 10.1053/j.gastro.2015.08.055] [Cited by in Crossref: 135] [Cited by in F6Publishing: 144] [Article Influence: 19.3] [Reference Citation Analysis]
278 Demenytė I, Strakšytė V, Gineikienė I, Basevičius A. MAGNETINIO REZONANSO ENTEROKOLONOGRAFIJOS PRITAIKYMO GALIMYBĖS ŽARNYNO LIGŲ DIAGNOSTIKOJE: LITERATŪROS APŽVALGA. Medicinos teorija ir praktika 2015;21:566-570. [DOI: 10.15591/mtp.2015.088] [Reference Citation Analysis]
279 Peyrin-biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'donnell S, Pariente B, Winer S, Hanauer S, Colombel J-. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. American Journal of Gastroenterology 2015;110:1324-38. [DOI: 10.1038/ajg.2015.233] [Cited by in Crossref: 1139] [Cited by in F6Publishing: 1169] [Article Influence: 162.7] [Reference Citation Analysis]
280 Winter DA, Karolewska-bochenek K, Lazowska-przeorek I, Lionetti P, Mearin ML, Chong SK, Roma-giannikou E, Maly J, Kolho K, Shaoul R, Staiano A, Damen GM, de Meij T, Hendriks D, George EK, Turner D, Escher JC. Pediatric IBD-unclassified Is Less Common than Previously Reported; Results of an 8-Year Audit of the EUROKIDS Registry: . Inflammatory Bowel Diseases 2015;21:2145-53. [DOI: 10.1097/mib.0000000000000483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
281 Martínez-Montiel MP, Casis-Herce B, Gómez-Gómez GJ, Masedo-González A, Yela-San Bernardino C, Piedracoba C, Castellano-Tortajada G. Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol 2015;8:257-69. [PMID: 26316792 DOI: 10.2147/CEG.S58152] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
282 Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-biroulet L, Straumann A, Rogler G, Schoepfer AM; the Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015;42:977-89. [DOI: 10.1111/apt.13363] [Cited by in Crossref: 76] [Cited by in F6Publishing: 78] [Article Influence: 10.9] [Reference Citation Analysis]
283 Aggarwal D, Limdi JK. Anti-TNF therapy is associated with a reduction in radiation exposure in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2015;27:13-9. [PMID: 25341058 DOI: 10.1097/MEG.0000000000000222] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
284 Kopylov U, Yablecovitch D, Lahat A, Neuman S, Levhar N, Greener T, Klang E, Rozendorn N, Amitai MM, Ben-Horin S, Eliakim R. Detection of Small Bowel Mucosal Healing and Deep Remission in Patients With Known Small Bowel Crohn's Disease Using Biomarkers, Capsule Endoscopy, and Imaging. Am J Gastroenterol. 2015;110:1316-1323. [PMID: 26215531 DOI: 10.1038/ajg.2015.221] [Cited by in Crossref: 98] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
285 Navas-lópez V, Blasco-alonso J, Lacasa Maseri S, Girón Fernández-crehuet F, Serrano Nieto M, Vicioso Recio M, Sierra Salinas C. Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn's disease in the era of biologics. Anales de Pediatría (English Edition) 2015;83:47-54. [DOI: 10.1016/j.anpede.2014.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
286 Vieth M, Atreya R, Neumann H. Carcinoma in inflammatory bowel disease: endoscopic advances, management, and specimen handling. A review for the pathologist. Diagnostic Histopathology 2015;21:290-298. [DOI: 10.1016/j.mpdhp.2015.06.024] [Reference Citation Analysis]
287 Civitelli F, Casciani E, Maccioni F, Oliva S, Al Ansari N, Bonocore V, Cucchiara S. Use of Imaging Techniques in Inflammatory Bowel Diseases That Minimize Radiation Exposure. Curr Gastroenterol Rep 2015;17. [DOI: 10.1007/s11894-015-0448-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
288 Jesuratnam-Nielsen K, Løgager VB, Munkholm P, Thomsen HS. Diagnostic accuracy of three different MRI protocols in patients with inflammatory bowel disease. Acta Radiol Open 2015;4:2058460115588099. [PMID: 26097746 DOI: 10.1177/2058460115588099] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
289 Yoshino T, Matsuura M, Minami N, Yamada S, Honzawa Y, Kimura M, Koshikawa Y, Madian A, Toyonaga T, Nakase H. Efficacy of Thiopurines in Biologic-Naive Japanese Patients With Crohn's Disease: A Single-Center Experience. Intest Res 2015;13:266-73. [PMID: 26131002 DOI: 10.5217/ir.2015.13.3.266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
290 Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416. [PMID: 25262067 DOI: 10.1007/s11894-014-0416-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
291 Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, Peyrin-Biroulet L, Danese S. Bowel Damage as Assessed by the Lémann Index is Reversible on Anti-TNF Therapy for Crohn's Disease. J Crohns Colitis 2015;9:633-9. [PMID: 25958059 DOI: 10.1093/ecco-jcc/jjv080] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
292 Chiorean L, Schreiber-Dietrich D, Braden B, Cui XW, Buchhorn R, Chang JM, Dietrich CF. Ultrasonographic imaging of inflammatory bowel disease in pediatric patients. World J Gastroenterol 2015; 21(17): 5231-5241 [PMID: 25954096 DOI: 10.3748/wjg.v21.i17.5231] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
293 Matsumoto T, Yanai S, Toya Y, Ueno M, Nakamura S. Internet-orientated Assessment of QOL and Actual Treatment Status in Japanese Patients with Inflammatory Bowel Disease: The 3I survey. J Crohns Colitis 2015;9:477-82. [PMID: 25814388 DOI: 10.1093/ecco-jcc/jjv052] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
294 Colombel J, Reinisch W, Mantzaris GJ, Kornbluth A, Rutgeerts P, Tang KL, Oortwijn A, Bevelander GS, Cornillie FJ, Sandborn WJ. Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONIC post hoc analysis. Aliment Pharmacol Ther 2015;41:734-46. [DOI: 10.1111/apt.13139] [Cited by in Crossref: 123] [Cited by in F6Publishing: 128] [Article Influence: 17.6] [Reference Citation Analysis]
295 Ruemmele FM, Hyams JS, Otley A, Griffiths A, Kolho KL, Dias JA, Levine A, Escher JC, Taminiau J, Veres G, Colombel JF, Vermeire S, Wilson DC, Turner D. Outcome measures for clinical trials in paediatric IBD: an evidence-based, expert-driven practical statement paper of the paediatric ECCO committee. Gut 2015;64:438-46. [PMID: 24821616 DOI: 10.1136/gutjnl-2014-307008] [Cited by in Crossref: 55] [Cited by in F6Publishing: 56] [Article Influence: 7.9] [Reference Citation Analysis]
296 Sorrentino D, Nash P, Viladomiu M, Hontecillas R, Bassaganya-Riera J. Stopping anti-TNF agents in patients with Crohn’s disease in remission: is it a feasible long-term strategy? Inflamm Bowel Dis. 2014;20:757-766. [PMID: 24572206 DOI: 10.1097/01.MIB.0000442680.47427.bf] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
297 Bryant R, Sandborn W, Travis S. Introducing Vedolizumab to Clinical Practice: Who, When, and How? Journal of Crohn's and Colitis 2015;9:356-66. [DOI: 10.1093/ecco-jcc/jjv033] [Cited by in Crossref: 44] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
298 Baumgart DC, Müller HP, Grittner U, Metzke D, Fischer A, Guckelberger O, Pascher A, Sack I, Vieth M, Rudolph B. US-based Real-time Elastography for the Detection of Fibrotic Gut Tissue in Patients with Stricturing Crohn Disease. Radiology. 2015;275:889-899. [PMID: 25668520 DOI: 10.1148/radiol.14141929] [Cited by in Crossref: 88] [Cited by in F6Publishing: 89] [Article Influence: 12.6] [Reference Citation Analysis]
299 Barrie AM, Regueiro M. Role of Mucosal Healing. Endoscopy in Inflammatory Bowel Disease 2015. [DOI: 10.1007/978-3-319-11077-6_12] [Reference Citation Analysis]
300 Gaya DR. Crohn's disease in remission or simply smouldering? Ann Gastroenterol 2015;28:157. [PMID: 25830690] [Reference Citation Analysis]
301 Yamada A, Takeuchi K, Arai T, Iwasa R, Ishikawa R, Suzuki Y. Predictions of relapse and the risk of surgery by cross-sectional imaging in patients with Crohn's disease : a comparison with double balloon enteroscopy. Prog dig Endosc 2015;86:79-82. [DOI: 10.11641/pde.86.1_79] [Reference Citation Analysis]
302 Mantzaris GJ, Viazis N, Polymeros D, Papamichael K, Bamias G, Koutroubakis IE. Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol 2015;28:417-25. [PMID: 26424173] [Reference Citation Analysis]
303 Scaioli E, Cardamone C, Scagliarini M, Zagari RM, Bazzoli F, Belluzzi A. Can fecal calprotectin better stratify Crohn's disease activity index? Ann Gastroenterol 2015;28:247-52. [PMID: 25831217] [Reference Citation Analysis]
304 Jang BI. Changing Paradigm in the Management of Inflammatory Bowel Disease. Korean J Gastroenterol 2015;65:268. [DOI: 10.4166/kjg.2015.65.5.268] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
305 Vanslembrouck R, Vanbeckevoort D, Chawla TP, Van Assche G. Magnetic Resonance Enterography. Endoscopy in Inflammatory Bowel Disease 2015. [DOI: 10.1007/978-3-319-11077-6_5] [Reference Citation Analysis]
306 Minar P, Haberman Y, Jurickova I, Wen T, Rothenberg ME, Kim MO, Saeed SA, Baldassano RN, Stephens M, Markowitz J, Rosh J, Crandall WV, Heyman MB, Mack DR, Griffiths AM, Baker SS, Hyams JS, Kugathasan S, Denson LA. Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis 2014;20:1037-48. [PMID: 24788216 DOI: 10.1097/MIB.0000000000000049] [Cited by in Crossref: 2] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
307 Iskandar HN, Cassell B, Kanuri N, Gyawali CP, Gutierrez A, Dassopoulos T, Ciorba MA, Sayuk GS. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease. J Clin Gastroenterol 2014;48:423-9. [PMID: 24406434 DOI: 10.1097/MCG.0000000000000049] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
308 Minordi LM, Scaldaferri F, Larosa L, Marra R, Giordano F, Laterza L, Scoleri I, Poscia A, Gerardi V, Bruno G, Gaetani E, Gasbarrini A, Vecchioli A, Bonomo L. Comparison between clinical and radiological evaluation before and after medical therapy in patients with Crohn's disease: new prospective roles of CT enterography. Radiol Med 2015;120:449-57. [PMID: 25450867 DOI: 10.1007/s11547-014-0471-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
309 Oh SH, Kim KM. Current issues of pediatric inflammatory bowel disease in Korea. Korean J Pediatr. 2014;57:465-471. [PMID: 25550700 DOI: 10.3345/kjp.2014.57.11.465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
310 Alrubaiy L, Dodds P, Hutchings HA, Russell IT, Watkins A, Williams JG. Development and validation of a new disease severity index: the Inflammatory Bowel Disease Index (IBDEX). Frontline Gastroenterol 2015;6:161-8. [PMID: 28839806 DOI: 10.1136/flgastro-2014-100530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
311 Spekhorst LM, Visschedijk MC, Alberts R, Festen EA, van der Wouden EJ, Dijkstra G, (ICC) RKWDIOCAC. Performance of the Montreal classification for inflammatory bowel diseases. World J Gastroenterol 2014; 20(41): 15374-15381 [PMID: 25386087 DOI: 10.3748/wjg.v20.i41.15374] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
312 Hindryckx P, Baert F, Hart A, Armuzzi A, Panès J, Peyrin-biroulet L. Clinical trials in luminal Crohn's disease: A historical perspective. Journal of Crohn's and Colitis 2014;8:1339-50. [DOI: 10.1016/j.crohns.2014.04.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
313 Watanabe M, Hibi T, Mostafa NM, Chao J, Arora V, Camez A, Petersson J, Thakkar R. Long-term safety and efficacy of adalimumab in Japanese patients with moderate to severe Crohn's disease. Journal of Crohn's and Colitis 2014;8:1407-16. [DOI: 10.1016/j.crohns.2014.04.012] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
314 Hyams JS. Biologics in pediatric Crohn’s disease: is it time to move to an earlier therapeutic approach? Expert Review of Clinical Immunology 2014;10:1423-6. [DOI: 10.1586/1744666x.2014.955017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
315 Connelly TM, Messaris E. Predictors of recurrence of Crohn’s disease after ileocolectomy: A review. World J Gastroenterol 2014; 20(39): 14393-14406 [PMID: 25339826 DOI: 10.3748/wjg.v20.i39.14393] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
316 Ruemmele F, Veres G, Kolho K, Griffiths A, Levine A, Escher J, Amil Dias J, Barabino A, Braegger C, Bronsky J, Buderus S, Martín-de-carpi J, De Ridder L, Fagerberg U, Hugot J, Kierkus J, Kolacek S, Koletzko S, Lionetti P, Miele E, Navas López V, Paerregaard A, Russell R, Serban D, Shaoul R, Van Rheenen P, Veereman G, Weiss B, Wilson D, Dignass A, Eliakim A, Winter H, Turner D. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. Journal of Crohn's and Colitis 2014;8:1179-207. [DOI: 10.1016/j.crohns.2014.04.005] [Cited by in Crossref: 686] [Cited by in F6Publishing: 709] [Article Influence: 85.8] [Reference Citation Analysis]
317 Bryant RV, Winer S, Travis SP, Riddell RH. Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? J Crohns Colitis. 2014;8:1582-1597. [PMID: 25267173 DOI: 10.1016/j.crohns.2014.08.011] [Cited by in Crossref: 183] [Cited by in F6Publishing: 193] [Article Influence: 22.9] [Reference Citation Analysis]
318 Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D’Haens G, Loftus EV, Louis E, Panés J, Schölmerich J. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52-63.e3. [PMID: 25241327 DOI: 10.1053/j.gastro.2014.09.015] [Cited by in Crossref: 207] [Cited by in F6Publishing: 212] [Article Influence: 25.9] [Reference Citation Analysis]
319 Spinelli A, Allocca M, Jovani M, Danese S. Review article: optimal preparation for surgery in Crohn's disease. Aliment Pharmacol Ther 2014;40:1009-22. [DOI: 10.1111/apt.12947] [Cited by in Crossref: 49] [Cited by in F6Publishing: 52] [Article Influence: 6.1] [Reference Citation Analysis]
320 Manser CN, Frei P, Grandinetti T, Biedermann L, Mwinyi J, Vavricka SR, Schoepfer A, Fried M, Rogler G. Risk Factors for Repetitive Ileocolic Resection in Patients with Crohnʼs Disease: Results of an Observational Cohort Study. Inflammatory Bowel Diseases 2014;20:1548-54. [DOI: 10.1097/mib.0000000000000123] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
321 Sandborn WJ, Hanauer S, Van Assche G, Panés J, Wilson S, Petersson J, Panaccione R. Treating beyond symptoms with a view to improving patient outcomes in inflammatory bowel diseases. J Crohns Colitis 2014;8:927-35. [DOI: 10.1016/j.crohns.2014.02.021] [Cited by in Crossref: 93] [Cited by in F6Publishing: 87] [Article Influence: 11.6] [Reference Citation Analysis]
322 Chehab M, Hlubocky J, Olariu E, Bloom D, Nandalur K. Comprehensive magnetic resonance enterography of Crohn's disease in the pediatric population: technique, interpretation, and management. Curr Probl Diagn Radiol 2015;44:193-206. [PMID: 25155516 DOI: 10.1067/j.cpradiol.2014.07.003] [Reference Citation Analysis]
323 Eliakim R, Magro F. Imaging techniques in IBD and their role in follow-up and surveillance. Nat Rev Gastroenterol Hepatol. 2014;11:722-736. [PMID: 25157623 DOI: 10.1038/nrgastro.2014.144] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.0] [Reference Citation Analysis]
324 Levesque BG, Sandborn WJ, Ruel J, Feagan BG, Sands BE, Colombel JF. Converging goals of treatment of inflammatory bowel disease from clinical trials and practice. Gastroenterology. 2015; 148:37-51.e1. [PMID: 25127678 DOI: 10.1053/j.gastro.2014.08.003] [Cited by in Crossref: 155] [Cited by in F6Publishing: 161] [Article Influence: 19.4] [Reference Citation Analysis]
325 Baudry C, Pariente B, Lourenço N, Simon M, Chirica M, Cattan P, Munoz-Bongrand N, Gornet JM, Allez M. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn’s disease: a retrospective study. Dig Liver Dis. 2014;46:887-892. [PMID: 25081846 DOI: 10.1016/j.dld.2014.07.005] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
326 Melchior C, Loeuillard E, Marion-Letellier R, Nicol L, Mulder P, Guerin C, Bôle-Feysot C, Aziz M, Déchelotte P, Vera P, Savoye G, Savoye-Collet C. Magnetic resonance colonography for fibrosis assessment in rats with chronic colitis. PLoS One 2014;9:e100921. [PMID: 25000184 DOI: 10.1371/journal.pone.0100921] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
327 Casciani E, Vincentiis CD, Polettini E, Masselli G, Nardo GD, Civitelli F, Cucchiara S, Gualdi GF. Imaging of the small bowel: Crohn’s disease in paediatric patients. World J Radiol 2014; 6(6): 313-328 [PMID: 24976933 DOI: 10.4329/wjr.v6.i6.313] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
328 Pariente B, Laharie D. Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2014;40:338-353. [PMID: 24957164 DOI: 10.1111/apt.12838] [Cited by in Crossref: 69] [Cited by in F6Publishing: 73] [Article Influence: 8.6] [Reference Citation Analysis]
329 Schaeffer DF, Walsh JC, Kirsch R, Waterman M, Silverberg MS, Riddell RH. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy. Hum Pathol 2014;45:1928-35. [PMID: 25022570 DOI: 10.1016/j.humpath.2014.05.016] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
330 D’Incà R, Caccaro R. Measuring disease activity in Crohn’s disease: what is currently available to the clinician. Clin Exp Gastroenterol. 2014;7:151-161. [PMID: 24876789 DOI: 10.2147/ceg.s41413] [Cited by in Crossref: 44] [Cited by in F6Publishing: 48] [Article Influence: 5.5] [Reference Citation Analysis]
331 Allocca M, Fiorino G, Vermeire S, Reinisch W, Cataldi F, Danese S. Blockade of lymphocyte trafficking in inflammatory bowel diseases therapy: importance of specificity of endothelial target. Expert Review of Clinical Immunology 2014;10:885-95. [DOI: 10.1586/1744666x.2014.917962] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
332 Yoneno K, Hisamatsu T, Matsuoka K, Okamoto S, Takayama T, Ichikawa R, Sujino T, Miyoshi J, Takabayashi K, Mikami Y, Mizuno S, Wada Y, Yajima T, Naganuma M, Inoue N, Iwao Y, Ogata H, Hasegawa H, Kitagawa Y, Hibi T, Kanai T. Risk and Management of Intra-Abdominal Abscess in Crohn's Disease Treated with Infliximab. Digestion 2014;89:201-8. [DOI: 10.1159/000360618] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
333 Hisamatsu T, Naganuma M, Matsuoka K, Kanai T. Diagnosis and management of intestinal Behçet’s disease. Clin J Gastroenterol. 2014;7:205-212. [PMID: 24883128 DOI: 10.1007/s12328-014-0488-0] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 6.1] [Reference Citation Analysis]
334 Stidham RW, Lee TC, Higgins PD, Deshpande AR, Sussman DA, Singal AG, Elmunzer BJ, Saini SD, Vijan S, Waljee AK. Systematic review with network meta-analysis: the efficacy of anti-TNF agents for the treatment of Crohn’s disease. Aliment Pharmacol Ther. 2014;39:1349-1362. [PMID: 24749763 DOI: 10.1111/apt.12749] [Cited by in Crossref: 132] [Cited by in F6Publishing: 141] [Article Influence: 16.5] [Reference Citation Analysis]
335 Ghosh S, Pariente B, Mould DR, Schreiber S, Petersson J, Hommes D. New tools and approaches for improved management of inflammatory bowel diseases. J Crohns Colitis. 2014;8:1246-1253. [PMID: 24742735 DOI: 10.1016/j.crohns.2014.02.026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
336 Gaya DR. Delivering optimal care for inflammatory bowel disease patients in Scotland in 2014. Scott Med J 2014;59:130-5. [PMID: 24728818 DOI: 10.1177/0036933014531540] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
337 Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, Naganuma M, Araki A, Watanabe M. Comparison of magnetic resonance and balloon enteroscopic examination of the small intestine in patients with Crohn's disease. Gastroenterology 2014;147:334-342.e3. [PMID: 24732015 DOI: 10.1053/j.gastro.2014.04.008] [Cited by in Crossref: 85] [Cited by in F6Publishing: 87] [Article Influence: 10.6] [Reference Citation Analysis]
338 Panés J, O'Connor M, Peyrin-Biroulet L, Irving P, Petersson J, Colombel JF. Improving quality of care in inflammatory bowel disease: what changes can be made today? J Crohns Colitis 2014;8:919-26. [PMID: 24713174 DOI: 10.1016/j.crohns.2014.02.022] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 6.3] [Reference Citation Analysis]
339 Bewtra M, Johnson FR. Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data. Patient 2013;6:241-55. [PMID: 24127239 DOI: 10.1007/s40271-013-0031-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 3.9] [Reference Citation Analysis]
340 Navas-López VM, Blasco-Alonso J, Lacasa Maseri S, Girón Fernández-Crehuet F, Serrano Nieto MJ, Vicioso Recio MI, Sierra Salinas C. [Exclusive enteral nutrition continues to be first line therapy for pediatric Crohn’s disease in the era of biologics]. An Pediatr (Barc). 2014;Epub ahead of print. [PMID: 24704330 DOI: 10.1016/j.anpedi.2014.02.027] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
341 Pola S, Santillan C, Levesque BG, Feagan BG, Sandborn WJ. An Overview of Magnetic Resonance Enterography for Crohn’s Disease. Dig Dis Sci 2014;59:2040-9. [DOI: 10.1007/s10620-014-3116-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
342 Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Review of Gastroenterology & Hepatology 2014;8:457-9. [DOI: 10.1586/17474124.2014.902302] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
343 Guellouz S, Pariente B, Benet C, Baudry C, Lourenco N, Kraemer A, Allez M, Gornet JM. Cephalic duodenopancreatectomy for hyperalgic duodenal Crohn's disease fistulized in the pancreatic gland. Case Rep Gastroenterol 2014;8:72-6. [PMID: 24748861 DOI: 10.1159/000360844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
344 Tielbeek JA, Löwenberg M, Bipat S, Horsthuis K, Ponsioen CY, D’Haens GR, Stoker J. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn’s disease. Inflamm Bowel Dis. 2013;19:1943-1950. [PMID: 23765176 DOI: 10.1097/mib.0b013e3182905536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 18] [Article Influence: 0.8] [Reference Citation Analysis]
345 Girolomoni G, Griffiths CEM, Krueger J, Nestle FO, Nicolas J, Prinz JC, Puig L, Ståhle M, van de Kerkhof PCM, Allez M, Emery P, Paul C. Early intervention in psoriasis and immune-mediated inflammatory diseases: A hypothesis paper. Journal of Dermatological Treatment 2014;26:103-12. [DOI: 10.3109/09546634.2014.880396] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
346 Chen QQ, Yan L, Wan J. Select a suitable treatment strategy for Crohn's disease: step-up or top-down. EXCLI J 2014;13:111-22. [PMID: 26417246] [Reference Citation Analysis]
347 Vaughn BP, Shah S, Cheifetz AS. The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol 2014;12:103-17. [PMID: 24395615 DOI: 10.1007/s11938-013-0008-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
348 Krishnareddy S, Swaminath A. When combination therapy isn’t working: Emerging therapies for the management of inflammatory bowel disease. World J Gastroenterol 2014; 20(5): 1139-1146 [PMID: 24574790 DOI: 10.3748/wjg.v20.i5.1139] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
349 Moran GW, Dubeau MF, Kaplan GG, Panaccione R, Ghosh S. Novel concepts in inflammatory bowel disease. British Medical Bulletin 2014;109:55-72. [DOI: 10.1093/bmb/ldt039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
350 Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29:397-404. [PMID: 23695427 DOI: 10.1097/mog.0b013e3283622914] [Cited by in Crossref: 62] [Cited by in F6Publishing: 66] [Article Influence: 7.8] [Reference Citation Analysis]
351 Rimola J, Ordás I. MR Colonography in Inflammatory Bowel Disease. Magnetic Resonance Imaging Clinics of North America 2014;22:23-33. [DOI: 10.1016/j.mric.2013.07.011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
352 Gerich ME, McGovern DP. Towards personalized care in IBD. Nat Rev Gastroenterol Hepatol. 2014;11:287-299. [PMID: 24345887 DOI: 10.1038/nrgastro.2013.242] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 5.0] [Reference Citation Analysis]
353 Marteau P, Allez M, Jian R. Enfermedad de Crohn. EMC - Tratado de Medicina 2013;17:1-8. [DOI: 10.1016/s1636-5410(13)65895-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
354 Orlando A, Guglielmi FW, Cottone M, Orlando E, Romano C, Sinagra E. Clinical implications of mucosal healing in the management of patients with inflammatory bowel disease. Digestive and Liver Disease 2013;45:986-91. [DOI: 10.1016/j.dld.2013.07.005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 3.8] [Reference Citation Analysis]
355 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn's disease monitoring. Gut 2013;62:1806-16. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 8.6] [Reference Citation Analysis]
356 Hordonneau C, Buisson A, Scanzi J, Goutorbe F, Pereira B, Borderon C, Da Ines D, Montoriol PF, Garcier JM, Boyer L, Bommelaer G, Petitcolin V. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn's disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89-98. [PMID: 24247212 DOI: 10.1038/ajg.2013.385] [Cited by in Crossref: 157] [Cited by in F6Publishing: 159] [Article Influence: 17.4] [Reference Citation Analysis]
357 García-López S. [Follow-up of patients with inflammatory bowel disease]. Gastroenterol Hepatol 2013;36 Suppl 2:30-8. [PMID: 24160950 DOI: 10.1016/S0210-5705(13)70051-7] [Reference Citation Analysis]
358 Speight RA, Mansfield JC. Drug advances in inflammatory bowel disease. Clin Med (Lond) 2013;13:378-82. [PMID: 23908509 DOI: 10.7861/clinmedicine.13-4-378] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
359 Miheller P, Mandel MD, Mullner K, Lakatos PL. Clinical aspects of mucosal healing in inflammatory bowel diseases: what is it and what is the real value for the everyday practice? Expert Rev Clin Immunol 2013;9:871-82. [PMID: 24070050 DOI: 10.1586/1744666X.2013.824675] [Reference Citation Analysis]
360 Makanyanga JC, Taylor SA. Current and future role of MR enterography in the management of Crohn disease. AJR Am J Roentgenol. 2013;201:56-64. [PMID: 23789658 DOI: 10.2214/ajr.12.10406] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 3.4] [Reference Citation Analysis]
361 Panaccione R, Colombel JF, Sandborn WJ, D’Haens G, Zhou Q, Pollack PF, Thakkar RB, Robinson AM. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013;38:1236-1247. [PMID: 24134498 DOI: 10.1111/apt.12499] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 8.8] [Reference Citation Analysis]
362 Makanyanga JC, Pendsé D, Dikaios N, Bloom S, Mccartney S, Helbren E, Atkins E, Cuthbertson T, Punwani S, Forbes A, Halligan S, Taylor SA. Evaluation of Crohn’s disease activity: Initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 2014;24:277-87. [DOI: 10.1007/s00330-013-3010-z] [Cited by in Crossref: 93] [Cited by in F6Publishing: 98] [Article Influence: 10.3] [Reference Citation Analysis]
363 Papay P, Ignjatovic A, Karmiris K, Amarante H, Miheller P, Feagan B, D'haens G, Marteau P, Reinisch W, Sturm A, Steinwurz F, Egan L, Panés J, Louis E, Colombel J, Panaccione R. Optimising monitoring in the management of Crohn's disease: A physician's perspective. Journal of Crohn's and Colitis 2013;7:653-69. [DOI: 10.1016/j.crohns.2013.02.005] [Cited by in Crossref: 79] [Cited by in F6Publishing: 85] [Article Influence: 8.8] [Reference Citation Analysis]
364 Amitai MM, Ben-horin S, Eliakim R, Kopylov U. Magnetic resonance enterography in Crohn's disease: A guide to common imaging manifestations for the IBD physician. Journal of Crohn's and Colitis 2013;7:603-15. [DOI: 10.1016/j.crohns.2012.10.005] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 4.1] [Reference Citation Analysis]
365 Mazzuoli S, Guglielmi FW, Antonelli E, Salemme M, Bassotti G, Villanacci V. Definition and evaluation of mucosal healing in clinical practice. Dig Liver Dis. 2013;45:969-977. [PMID: 23932331 DOI: 10.1016/j.dld.2013.06.010] [Cited by in Crossref: 91] [Cited by in F6Publishing: 96] [Article Influence: 10.1] [Reference Citation Analysis]
366 Strauss C. L’entéro-IRM : comment et quand la réaliser ? comment l’interpréter ? Colon Rectum 2013;7:169-175. [DOI: 10.1007/s11725-013-0464-8] [Reference Citation Analysis]
367 Mclaughlin PD, Maher MM. Nonneoplastic Diseases of the Small Intestine: Differential Diagnosis and Crohn Disease. American Journal of Roentgenology 2013;201:W174-82. [DOI: 10.2214/ajr.12.8495] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
368 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
369 Zallot C, Peyrin-Biroulet L. Deep remission in inflammatory bowel disease: looking beyond symptoms. Curr Gastroenterol Rep. 2013;15:315. [PMID: 23354742 DOI: 10.1007/s11894-013-0315-7] [Cited by in Crossref: 86] [Cited by in F6Publishing: 97] [Article Influence: 9.6] [Reference Citation Analysis]
370 Alrubaiy L, Hutchings HA, Williams JG. Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open 2013;3:e003192. [PMID: 23842503 DOI: 10.1136/bmjopen-2013-003192] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
371 Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut 2013;62:1072-84. [PMID: 23626373 DOI: 10.1136/gutjnl-2012-304353] [Cited by in Crossref: 296] [Cited by in F6Publishing: 305] [Article Influence: 32.9] [Reference Citation Analysis]
372 Rimola J, Ordás I, Rodríguez S, Ricart E, Panés J. Imaging indexes of activity and severity for Crohn's disease: current status and future trends. Abdom Imaging 2012;37:958-66. [PMID: 22072290 DOI: 10.1007/s00261-011-9820-z] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
373 Roblin X, Dronne W, Paul S, Tedesco ED. New strategies for the treatment of inflammatory bowel diseases. Clinical Investigation 2013;3:479-492. [DOI: 10.4155/cli.13.26] [Reference Citation Analysis]
374 Chowers Y. Taking Crohn's disease personally. Rambam Maimonides Med J 2013;4:e0011. [PMID: 23908861 DOI: 10.5041/RMMJ.10111] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Panes J, Bouhnik Y, Reinisch W, Stoker J, Taylor SA, Baumgart DC, Danese S, Halligan S, Marincek B, Matos C. Imaging techniques for assessment of inflammatory bowel disease: Joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis. 2013;7:556-585. [PMID: 23583097 DOI: 10.1016/j.crohns.2013.02.020] [Cited by in Crossref: 458] [Cited by in F6Publishing: 476] [Article Influence: 50.9] [Reference Citation Analysis]
376 Marteau P, Allez M, Jian R. Maladie de Crohn. EMC - Traité de médecine AKOS 2013;8:1-8. [DOI: 10.1016/s1634-6939(12)60224-5] [Reference Citation Analysis]
377 Fischer A, Gluth M, Pape UF, Wiedenmann B, Theuring F, Baumgart DC. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF-α on tight junction proteins and signaling pathways in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2013;304:G970-G979. [PMID: 23538493 DOI: 10.1152/ajpgi.00183.2012] [Cited by in Crossref: 80] [Cited by in F6Publishing: 82] [Article Influence: 8.9] [Reference Citation Analysis]
378 Atreya R, Neumann H, Neurath MF. [Rational treatment of Crohn's disease]. MMW Fortschr Med 2013;155:61-3. [PMID: 23614201 DOI: 10.1007/s15006-013-0230-8] [Reference Citation Analysis]
379 Peyrin-Biroulet L, Fiorino G, Buisson A, Danese S. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat Rev Gastroenterol Hepatol 2013;10:345-51. [PMID: 23458890 DOI: 10.1038/nrgastro.2013.31] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
380 Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, Lembo A, Leffler D, Moss AC, Cheifetz AS. The Crohn's disease activity index (CDAI) is similarly elevated in patients with Crohn's disease and in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2013;37:786-794. [PMID: 23432394 DOI: 10.1111/apt.12262] [Cited by in Crossref: 74] [Cited by in F6Publishing: 80] [Article Influence: 8.2] [Reference Citation Analysis]
381 Buisson A, Joubert A, Montoriol PF, Da Ines D, Hordonneau C, Pereira B, Garcier JM, Bommelaer G, Petitcolin V. Diffusion-weighted magnetic resonance imaging for detecting and assessing ileal inflammation in Crohn's disease. Aliment Pharmacol Ther. 2013;37:537-545. [PMID: 23289713 DOI: 10.1111/apt.12201] [Cited by in Crossref: 144] [Cited by in F6Publishing: 148] [Article Influence: 16.0] [Reference Citation Analysis]
382 Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 2012;30 Suppl 3:100-106. [PMID: 23295699 DOI: 10.1159/000342731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
383 Colombel JF, Louis E, Peyrin-Biroulet L, Sandborn WJ, Panaccione R. Deep remission: a new concept? Dig Dis. 2012;30 Suppl 3:107-111. [PMID: 23295700 DOI: 10.1159/000342732] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
384 Zallot C, Peyrin-Biroulet L. Clinical risk factors for complicated disease: how reliable are they? Dig Dis. 2012;30 Suppl 3:67-72. [PMID: 23295694 DOI: 10.1159/000342608] [Cited by in Crossref: 53] [Cited by in F6Publishing: 55] [Article Influence: 5.9] [Reference Citation Analysis]
385 Halfvarson J. Genetic Epidemiology of Inflammatory Bowel Disease, Early Twin and Family Studies. Molecular Genetics of Inflammatory Bowel Disease 2013. [DOI: 10.1007/978-1-4614-8256-7_2] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
386 Peyrin-biroulet L, Billioud V, D'haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PDR, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel J, Travis S, Sandborn WJ. Development of the Paris Definition of Early Crohn's Disease for Disease-Modification Trials: Results of an International Expert Opinion Process. American Journal of Gastroenterology 2012;107:1770-6. [DOI: 10.1038/ajg.2012.117] [Cited by in Crossref: 77] [Cited by in F6Publishing: 78] [Article Influence: 7.7] [Reference Citation Analysis]
387 D'haens G, Feagan B, Colombel J, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary J, Danese S, Fedorak RN, Hanauer S, Lémann M. Challenges to the Design, Execution, and Analysis of Randomized Controlled Trials for Inflammatory Bowel Disease. Gastroenterology 2012;143:1461-9. [DOI: 10.1053/j.gastro.2012.09.031] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
388 Kruis W, Katalinic A, Klugmann T, Franke GR, Weismüller J, Leifeld L, Ceplis-Kastner S, Reimers B, Bokemeyer B. Predictive factors for an uncomplicated long-term course of Crohn's disease: a retrospective analysis. J Crohns Colitis 2013;7:e263-70. [PMID: 23182164 DOI: 10.1016/j.crohns.2012.10.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
389 Rahier J, Pariente B, Colombel J. Skipping Crohn's Disease: When Ileocolonoscopy Is Not Enough. Clinical Gastroenterology and Hepatology 2012;10:1260-1. [DOI: 10.1016/j.cgh.2012.06.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
390 Savoye G, Salleron J, Gower-rousseau C, Dupas J, Vernier-massouille G, Fumery M, Merle V, Lerebours E, Cortot A, Turck D, Salomez J, Lemann M, Colombel J, Duhamel A. Clinical predictors at diagnosis of disabling pediatric Crohnʼs disease: . Inflammatory Bowel Diseases 2012;18:2072-8. [DOI: 10.1002/ibd.22898] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
391 Baumgart DC, Sandborn WJ. Crohn's disease. The Lancet 2012;380:1590-605. [DOI: 10.1016/s0140-6736(12)60026-9] [Cited by in Crossref: 1283] [Cited by in F6Publishing: 1376] [Article Influence: 128.3] [Reference Citation Analysis]
392 Al-Hawary M, Zimmermann EM. A new look at Crohn’s disease: novel imaging techniques. Curr Opin Gastroenterol. 2012;28:334-340. [PMID: 22678451 DOI: 10.1097/mog.0b013e3283540705] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 0.3] [Reference Citation Analysis]
393 Di Nardo G, Aloi M, Oliva S, Civitelli F, Casciani E, Cucchiara S. Investigation of small bowel in pediatric Crohnʼs disease: . Inflammatory Bowel Diseases 2012;18:1760-76. [DOI: 10.1002/ibd.22885] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
394 Absah I, Bruining DH, Matsumoto JM, Weisbrod AJ, Fletcher JG, Fidler JL, Faubion WA. MR Enterography in Pediatric Inflammatory Bowel Disease: Retrospective Assessment of Patient Tolerance, Image Quality, and Initial Performance Estimates. American Journal of Roentgenology 2012;199:W367-75. [DOI: 10.2214/ajr.11.8363] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 4.3] [Reference Citation Analysis]
395 Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol 2012; 18(29): 3823-3827 [PMID: 22876033 DOI: 10.3748/wjg.v18.i29.3823] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
396 Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn’s disease. J Crohns Colitis. 2012;6 Suppl 2:S235-S242. [PMID: 22463930 DOI: 10.1016/s1873-9946(12)60503-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
397 Hommes D, Colombel JF, Emery P, Greco M, Sandborn WJ. Changing Crohn’s disease management: need for new goals and indices to prevent disability and improve quality of life. J Crohns Colitis. 2012;6 Suppl 2:S224-S234. [PMID: 22463929 DOI: 10.1016/s1873-9946(12)60502-9] [Cited by in Crossref: 57] [Cited by in F6Publishing: 61] [Article Influence: 5.7] [Reference Citation Analysis]
398 Louis E. Epidemiology of the transition from early to late Crohn’s disease. Dig Dis. 2012;30:376-379. [PMID: 22796799 DOI: 10.1159/000338129] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
399 Helbren EL, Plumb AA, Taylor SA. The future developments in gastrointestinal radiology. Frontline Gastroenterol 2012;3:i36-41. [PMID: 28839691 DOI: 10.1136/flgastro-2012-100121] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
400 Schreiber S, Reinisch W, Colombel JF, Sandborn WJ, Hommes DW, Robinson AM, Huang B, Lomax KG, Pollack PF. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease. J Crohns Colitis. 2013;7:213-221. [PMID: 22704916 DOI: 10.1016/j.crohns.2012.05.015] [Cited by in Crossref: 117] [Cited by in F6Publishing: 128] [Article Influence: 11.7] [Reference Citation Analysis]
401 Armuzzi A, Van Assche G, Reinisch W, de Chambrun GP, Griffiths A, Sladek M, Preiss JC, Lukas M, D'haens G. Results of the 2nd scientific workshop of the ECCO (IV): Therapeutic strategies to enhance intestinal healing in inflammatory bowel disease. Journal of Crohn's and Colitis 2012;6:492-502. [DOI: 10.1016/j.crohns.2011.12.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
402 Louis E, Mary J, Colombel J. Reply. Gastroenterology 2012;142:e18. [DOI: 10.1053/j.gastro.2012.03.031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
403 Danese S, Peyrin-biroulet L. Mucosal healing—EXTENDing our knowledge in Crohn's disease. Nat Rev Gastroenterol Hepatol 2012;9:309-11. [DOI: 10.1038/nrgastro.2012.77] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
404 Hustinx R. The Utility of FDG PET/CT in Inflammatory Bowel Disease. PET Clinics 2012;7:219-25. [DOI: 10.1016/j.cpet.2012.01.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
405 Onali S, Calabrese E, Pallone F. Measuring disease activity in Crohn’s disease. Abdom Imaging 2012;37:927-32. [DOI: 10.1007/s00261-012-9877-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
406 Calabrese E, Zorzi F, Zuzzi S, Ooka S, Onali S, Petruzziello C, Lasinio GJ, Biancone L, Rossi C, Pallone F. Development of a numerical index quantitating small bowel damage as detected by ultrasonography in Crohn’s disease. J Crohns Colitis. 2012;6:852-860. [PMID: 22398077 DOI: 10.1016/j.crohns.2012.01.015] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 4.2] [Reference Citation Analysis]
407 Peyrin-Biroulet L, Cieza A, Sandborn WJ, Coenen M, Chowers Y, Hibi T, Kostanjsek N, Stucki G, Colombel JF; International Programme to Develop New Indexes for Crohn's Disease (IPNIC) group. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012;61:241-7. [PMID: 21646246 DOI: 10.1136/gutjnl-2011-300049] [Cited by in Crossref: 215] [Cited by in F6Publishing: 228] [Article Influence: 21.5] [Reference Citation Analysis]
408 Sandborn WJ. The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here? Dig Dis 2012;30:140-4. [DOI: 10.1159/000342742] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
409 Torres J, Billioud V, Sachar DB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis as a progressive disease: the forgotten evidence. Inflamm Bowel Dis. 2012;18:1356-1363. [PMID: 22162423 DOI: 10.1002/ibd.22839] [Cited by in Crossref: 147] [Cited by in F6Publishing: 158] [Article Influence: 13.4] [Reference Citation Analysis]
410 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.2142] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
411 Fiorino G, Bonifacio C, Malesci A, Balzarini L, Danese S. MRI in Crohn’s disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol. 2012;9:23-31. [PMID: 22105109 DOI: 10.1038/nrgastro.2011.214] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
412 Cipriano LE, Levesque BG, Zaric GS, Loftus EV Jr, Sandborn WJ. Cost-effectiveness of imaging strategies to reduce radiation-induced cancer risk in Crohn's disease. Inflamm Bowel Dis 2012;18:1240-8. [PMID: 21928375 DOI: 10.1002/ibd.21862] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.8] [Reference Citation Analysis]
413 Burger D, Travis S. Conventional Medical Management of Inflammatory Bowel Disease. Gastroenterology 2011;140:1827-1837.e2. [DOI: 10.1053/j.gastro.2011.02.045] [Cited by in Crossref: 145] [Cited by in F6Publishing: 158] [Article Influence: 13.2] [Reference Citation Analysis]
414 Hara AK, Swartz PG. CT enterography of Crohn’s disease. Abdom Imaging. 2009;34:289-295. [PMID: 18649092 DOI: 10.1007/s00261-015-0357-4] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 4.7] [Reference Citation Analysis]
415 Matsuura R, Watanabe O, Nakamura M, Yamamura T, Matsushita M, Suhara H, Furukawa K, Ishikawa T, Funasaka K, Ohno E, Kawashima H, Miyahara R, Hirooka Y, Goto H. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn's disease according to double-balloon endoscopy findings. Nagoya J Med Sci 2018;80:257-66. [PMID: 29915443 DOI: 10.18999/nagjms.80.2.257] [Cited by in F6Publishing: 2] [Reference Citation Analysis]